AU2015234306A1 - Tfpi inhibitors and methods of use - Google Patents

Abstract

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject. 2fl/0Q/1 F

Description

Regulation 3.2 Revised 2/98 AUSTRALIA Patents Act, 1990 ORIGINAL COMPLETE SPECIFICATION APPLICANT/S: Baxter International Inc. (a Delaware Corporation) Baxter Healthcare SA INVENTORS: DOCKAL, Michael EHRLICH, Hartmut, Dr. SCHEIFLINGER, Friedrich REIMER, Ulf REINEKE, Ulrich POLAKOWSKI, Thomas SCHNEIDER, Eberhard ADDRESS FOR SERVICE: Peter Maxwell and Associates Level 6 60 Pitt Street SYDNEY NSW 2000 INVENTION TITLE: TFPI INHIBITORS AND METHODS OF USE DETAILS OF ASSOCIATED APPLICATION NO(S): Divisional of Australian Patent Application No. 2009 327 338 filed on 21 December 2009 The following statement is a full description of this invention including the best method of performing it known to us: 1 m:\docs\20091214\377184.doc TFPI INHIBITORS AND METHODS OF USE TECHNICAL FIELD OF THE INVENTION [0001] The invention generally relates to peptides that bind Tissue Factor Pathway Inhibitor (TFPI) and uses thereof. CROSS REFERENCE TO RELATED APPLICATIONS AND INCORPORATION BY REFERENCE [0002] This application claims priority to U.S. Provisional Patent Application No. 61/139,272, filed December 19, 2008, the disclosure of which is incorporated by reference in its entirety. BACKGROUND OF THE INVENTION [0003] Hemostasis relies on the complex coagulation cascade, wherein a series of events mediated by blood clotting factors lead to conversion of prothrombin to thrombin. Factor X (FX) activation is the central event of both the intrinsic and extrinsic pathways of the coagulation cascade. The extrinsic pathway has been proposed as the primary activator of the coagulation cascade (Mackman et al., Arterioscler. Thromb. Casc. BioL, 27, 1687-1693 (2007)). Circulating Tissue Factor (TF) and activated Factor Vii (FVIla) interact to form the "extrinsic complex," which mediates activation of FX. The coagulation cascade is amplified by the intrinsic pathway, during which successive activation of factors XII, XI, IX, and VIII results in formation of the "intrinsic" FIXa-FVIla complex that also mediates FX activation. Activated FX promotes thrombin formation, which is required for the body to create fibrin and effectively curb bleeding. [0004] Severe bleeding disorders, such as hemophilia, result from disruption of the blood coagulation cascade. Hemophilia A, the most common type of hemophilia, stems from a deficiency in factor Viii, while hemophilia B is associated with deficiencies in Factor IX (FIX). Hemophilia C is caused by a deficiency in Factor XI (FXI) (Cawthern et a]., Blood, 91(12), 4581-4592 (1998)). There is currently no cure for hemophilia and other clotting diseases. Factor replacement therapy is the most common treatment for blood coagulation disorders. However, blood clotting factors typically are cleared from the bloodstream shortly after administration. To be effective, a patient must receive frequent intravenous infusions of I M plasma-derived or recombinant factor concentrates, which is uncomfortable, requires clinical settings, is expensive, and is time consuming. In addition, therapeutic efficacy of factor replacement therapy can diminish drastically upon formation of inhibitory antibodies. Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies that neutralize Factor VIII (FVIII) (Peerlinck and Hermans, Haemophilia, 12, 579-590 (2006)). Few therapeutic options exist for patients with anti-Factor antibodies. [0005] Thus, there exists a need in the art for compositions and methods for treating blood coagulation disorders. The invention provides such compositions and methods. SUMMARY OF THE INVENTION [0006] The invention provides peptides that bind to Tissue Factor Pathway Inhibitor (TFPI), including TFPI antagonistic peptides having the ability to modulate the blood coagulation cascade. For example, the invention provides a peptide comprising the amino acid sequence X 7 XsX 9 Xr oXi 1

X

12

X

13

X

14 XsX;Xi 7

XISX

1 9

X

0

X

2 (SEQ ID NO: 3109), wherein

X

7 is selected from the group consisting of L, P. K, S, W, V, N, and Q;

X

8 is selected from the group consisting of L, R. N, F, and I;

X

9 is selected from the group consisting of Y, V, P, and C; Xio is selected from the group consisting of F, L, and G;

X

1 is selected from the group consisting of L, W, V, A, M, T, and S;

X

12 is selected from the group consisting of T, F, V, R, A, D, L, F, S, and Y;

X

13 is selected from the group consisting of I, M, G, Q, D, and R;

X

14 is selected from the group consisting of G, W, Y, L, M, and H;

X

15 is selected from the group consisting of N, P, F, H, K, and Y;

X

16 is selected from the group consisting of M, D, E, V, G, and K;

X

17 is selected from the group consisting of G, 1, R, S, T, and L; Xis is selected from the group consisting of M, K, L, and I;

X

19 is selected from the group consisting of Y, G, R, and S;

X

2 0 is selected from the group consisting of A, E, S, C, and Y; and

X

2 1 is selected from the group consisting of A, V, K, and E. [0007] In one aspect, the peptide comprises one or more N-terminal amino acid(s) directly linked to X 7 , wherein the N-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of 2

X

6 ,

X

5

X

6 ,

X

4

X

5

X

6 ,

X

3

X

4

X

5

X

6 (SEQ ID NO: 3110)

X

2

X

3

X

4

X

5

X

6 (SEQ ID NO: 3111), and

X

1

X

2

X

3

X

4

X

5

X

6 (SEQ ID NO: 3112), wherein

X

1 is selected from the group consisting of T and G; X 2 is selected from the group consisting of F and V; X 3 is selected from the group consisting of V, W, Y, and F; X4 is selected from the group consisting of D, Q, and S; X 5 is selected from the group consisting of E, T, N, and S; and X 6 is selected from the group consisting of R, H, K, and A. [0008] Alternatively or in addition, the peptide comprises one or more C-terminal amino acids directly linked to X 2 1 , wherein the C-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of

X

22 ,

X

22

X

2 3 ,

X

22

X

23

X

24 , X22X23X2 4

X

2 5(SEQ ID NO: 3113), X22X2 3

X

24

X

2 5

X

26 (SEQ ID NO: 3114), and

X

22 X2 3 X2 4 X25X2X2 7 (SEQ ID NO: 3115), wherein X22 is selected from the group consisting of Q, 1, E, W, R, L. and N; Xr is selected from the group consisting of L, V, M, and R; X24 is selected from the group consisting of K, L, A, and Y; X 25 is F; X 26 is G; and X27 is T. [0009] In one aspect, the invention provides a peptide comprising the amino acid sequence set forth in SEQ ID NOs: 1-7, such as a peptide comprising the amino acid sequence set forth in any one of JBT01.32, JBT0303, JBT0193, JBT01 78, JBT0120, and JBT0224, which inhibits TFPI activity within the blood coagulation cascade. The invention also provides a peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence Phe-Gln-Ser-Lys-Gly-Asn-Val-Phe-Val-A sp-Gly-Tyr-Phe-Glu-Arg-Leu-Arg-Ala Lys-Leu (FQSKGNVFVDGYFERLRAKL) (SEQ ID NO: 32). [00101 In addition, the invention provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (1): X1001-X1002-X1003-X1004-X1005-X1006-X1007 X1008-X1009-X10-X101l-X1.012-X1o13-X 14-X115-Xi016-X1o17-X1Os-X1019 X1020 (SEQ ID NO: 3116). In formula (1), 3 X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y; X1002 is an amino acid selected from the group consisting of G and Q; X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; X1004 is an amino acid selected from the group consisting of A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y; X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y; X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y; X1 007 is an amino acid selected from the group consisting of A, F, i, K, L, Nmv, P, Q, S, V, W and Y; X1 008 is an amino acid selected from the group consisting of F, H, K, W and Y; X1 009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V; X1010 is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, i, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y; X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg; X1012 is Y; X1 013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y; X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, i, K, L, M, N, P, Q, R, S, T, V, W and Y; X 1015 is an amino acid selected from the group consisting of (omega-methy)-R, D, E, K and R ; X1016 is L; X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hie, 1, K, L, M, N, Ne, Nva, Opa, Orn, Q, R, S, T, V, W and Y; 4 X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M. N, Q, R, S, T, V, W and Y; X1019 is an amino acid selected from the group consisting of Bhk, K, R and V; and X 1020 is either present or absent, whereby, in case X1020 is present, it is an amino acid selected from the group consisting of Aib, Bhl, C, F, G, H, 1, K, L, Nm], Q, R, S, T, V, W and Y. [0011] In one aspect, the peptide that binds TFPI comprises the structure of formula (III): X1001-Q-X1003-X1004-X1005-X1006-I/V-XIOOS-V-X1OO-G-Y-C/F-X1014-R-L-XI017 X1018-K-K/L (III) (SEQ ID NO: 3117). In formula (III), X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 are each independently selected from any amino acid. [0012] The invention further provides a TFPI-binding peptide comprising the structure of formula (V): X200I-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010 X2011 -X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022 X2023 (V) (SEQ ID NO: 3118). In formula (V), X2001, X2002, and X2023 independently are either present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F., G, H, 1, K, L, P, R, S, T, V and W; and X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S. T, V and W. Additionally, X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y; X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W; X2005 is W; X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R V and W; X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy; X2008 is an amino acid selected from the group consisting of A, G, R, S and T; X2009 is an amino acid selected from the group consisting of a, A, 1. K, L, M, m, Nie, p, R, and V; 5 X2010 is an amino acid selected from the group consisting of A, G, 1, K, L, P, R, S, T and V; X2011 is an amino acid selected from the group consisting of D, E, G, S and T; X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, 1, K, k, L, 1, M, m, Nle, nle, P, p, R, r, S, s, T, t, V, v, W and w; X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, 1, K, L, R, S, s, T, V and W; X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I. K, L, M, R, S, T, V and W; X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W; X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, T, V. W and Y; X2017 is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, S, T, V, W and Y; X2018 is an amino acid selected from the group consisting of C and D (preferably X2018 is C); X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W; X2020 is an amino acid selected from the group consisting of F and W; X2021 is an amino acid selected from the group consisting of 1, L and V; and X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W. When X2023 is present in the peptide, X2023 is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, S, T, V, W and Y. The peptide comprises a cyclic structure generated by a linkage between X2007 and X2018, indicated in Formula (V) by brackets. [0013] The invention also provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (VI): X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V X2010-D-X2012-X20 13-G-I/T-X2016-S/T-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119). In formula (VI), X2001, X2002 and X2023 are each independently present or absent. 6 X2008, X2010, X2012, X2013, X201 6 and X2022, as well as X2001, X2002, and X2023 when present, are each independently selected from any amino acid. The peptide comprises a cyclic structure generated by a linkage between X2007 and X2018, indicated in Formula (VI) by brackets. [0014] In one aspect, the invention provides a peptide that binds TFPL wherein the peptide comprises the structure of formula (VIII): X3001-X3002-X3003-X3004-X3005-X3006 X3007-X3008-X3009-X3010-X301 1-X3012-X3013-X3014-X3015-X3016-X3017-X3018 X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In formula (VIII), X3001 and X3002 are each independently present or absent. When present, X3001 is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y; and X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y. G, I and L. With respect to the remainder of formula (VIII), X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y; X3004 is an amino acid selected from the group consisting of A, C. D, E, F, G, H, 1, K, L, M, N, Q, R, S. T. V, W, Y and P; X3005 is an amino acid selected from the group consisting of C, D, F, G, H, 1, K, L, M, N, P, R, S, T, V, W and Y; X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H; X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, 1. K, L, N, R. S, T, W and Y; X3008 is an amino acid selected from the group consisting of A, C, F, G. H, K, L, M, N, P, Q, R, S, T, V, W, Y and I; X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K; X3010 is an amino acid selected from the group consisting of A, C. F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; X3011 is an amino acid selected from the group consisting of A, G, 1, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H; X3012 is an amino acid selected from the group consisting of A, C, H, 1, K. L and R; 7 X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I; X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K; X3015 is an amino acid selected from the group consisting of A, K and R; X3016 is an amino acid selected from the group consisting of A, F, K and R; X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q. R, S, T, V, W, Y, H, A and M; X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y; X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V. W, Y and I; X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P; and X3021 is an amino acid selected from the group consisting of A, C, H, I., K, L, M, N, P, Q, R, T, V, W, Y, F and G. [0015] Additionally, the invention provides a TFPI-binding peptide comprising the structure of formula (IX): X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008 X3009-X301.0-X301 1-H-X3013-X3014-K/R-R-X301.7-X301 S-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121), wherein X3001, X3002, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. In addition, the invention includes a peptide that binds TFPI, wherein the peptide comprises an amino acid sequence having at least 60% identity to the sequence of formula (X): Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (SEQ ID NO: 223). In the context of the disclosure, any peptide encompassed by any of formulas (1) to (X) and any TFPI-binding peptide described herein is also referred to as "the peptide of the invention" and as "a peptide as described herein." [0016] In some embodiments, the peptide of the invention binds TFPI- I (e.g., TFPI- 1a) and, optionally, improves TFPI-regulated thrombin generation in the absence of FVIII, FIX, and/or FXI. A composition (e.g., a pharmaceutical composition) comprising the peptide also is provided. 8 [0017] In addition, the invention provides methods of using the peptide of the invention. For example, the invention provides a method of inhibiting a TFPJ comprising contacting the TFPI with a peptide as described herein. The invention also provides a method of enhancing thrombin formation in a clotting factor-deficient subject, a method for increasing blood clot formation in a subject, and a method of treating a blood coagulation disorder in a subject. The methods are, in their entirety, also referred to herein as, e.g., "the method of the invention." The methods comprise administering to the subject a peptide as provided herein in an amount effective to enhance thrombin formation, an amount effective to enhance blood clot formation, or an amount effective to treat the blood coagulation disorder in the subject, Unless explicitly indicated to the contrary, the description provided herein with respect to one peptide of the invention or method of the invention applies to each and every peptide of the invention and method of the invention, respectively. Further aspects of the invention include use of the peptide of the invention for the manufacture of a medicament, a method for targeting a cell displaying TFPI, a method for treating or diagnosing a subject suffering from a disease or at risk of suffering from a disease, and a method of purifying TFPl. The preceding methods are, in their entirety, also referred to herein as, e.g., "the method of the invention." DESCRIPTION OF THE FIGURES [0018] Figure I is an illustration of the blood coagulation cascade. [0019] Figure 2 is an illustration of the secondary structure of Tissue Factor Pathway Inhibitor-1. [0020] Figure 3 is an illustration of the formation of a quaternary complex comprising Tissue Factor, Factor Xa (FXa), Factor VIla (FVIla), and TFPL. [0021] Figure 4 is a listing of amino acid sequences of various TFPI-inhibitory peptides denoting amino acid substitutions (bolded and underlined) in reference to peptide JBT0293. [0022] Figure 5 is an illustration of mRNA display selection of TFPI-inhibitor peptides. [0023] Figure 6A is an illustration of the ECoo binding ELISA and Figure 6B is an illustration of the IC 50 ELISA described in Example 1. [0024] Figure 7 is a binding ELISA curve comparing % OD (y-axis) and concentration [nM] (x-axis) for biotinylated peptide JBT01 32. 9 [0025] Figures 8A-8D are competition ELISA curves comparing % OD (y-axis) and concentration [nM] (x-axis) for exemplary peptides of the invention. [0026] Figures 9A and 9B are sensorgrams plotting RU (y-axis) against time in seconds (x axis) for peptides JBT0120 and JBT0132. [0027] Figures 1 OA and lOB are sensorgrams plotting RU (y-axis) against time in seconds (x-axis) for peptide JBT0120 interaction with Tissue Factor Pathway Inhibitor-I and Tissue Factor Pathway Inhibitor-2. [0028] Figures lIA and 1 1B are graphs comparing amount of thrombin generated (nM) (y axis) and time in minutes (x-axis) for peptide JBT0120 and peptide JBTO132 in a plasma based assay. [0029] Figures 12-18 are tables listing the amino acid sequences of various TFPI inhibitory peptides; EC 50 and percent inhibition of TFPI observed in the FXa inhibition assay; ECso and percent inhibition of TFPI observed in the extrinsic tenase inhibition assay; and FEIBA, Factor VIII (FVIII) Immunate, or Factor IX (FIX) equivalent activities (mU/mL) in plasma-based assays. "*" denotes negative controls. [0030] Figures 19-21 are tables listing the results from BlAcore analysis of several TFPI binding peptides. "*" denotes negative controls. [0031] Figures 22-30 are tables listing the amino acid sequences of various TFPI-binding peptides; EC5o and percent inhibition of TFPI observed in the FXa inhibition assay; ECo and percent inhibition of TFPI observed in the extrinsic tenase inhibition assay; and FEIBA, FVIII Immunate, or FIX equivalent activities (mU/mL) in plasma-based assays. "*" denotes negative controls. [0032] Figure 31 is a graph comparing a pharmacokinetic characteristic (concentration of peptide (y-axis) versus time after administration (x-axis)) of a PEGylated TFPI-binding peptide to the pharmacokinetic characteristic of same peptide lacking PEG. The peptides were administered intravenously to C57B16 mice at a dose of 10 mg/kg. Three biological samples were analyzed for the presence of peptide at each time point. [0033] Figures 32-39 are tables listing the amino acid sequences and IC 5 o or ECs 0 values of various peptides of the invention. "*" denotes negative controls. 10 DETAILED DESCRIPTION OF THE INVENTION [0034] The invention provides peptides that block the inhibitory activity of Tissue Factor Pathway Inhibitor-I (herein referred to as TFPI) within the blood coagulation cascade. Upon vascular injury, Tissue Factor (TF) complexes with Factor Vlla to form the "extrinsic complex" or "extrinsic tenase complex," which activates Factors IX and X (Figure 1). TFPI is the main natural regulator of TF/FVIIa extrinsic complex activity and by extension, plays a role in controlling thrombin generation (Panteleev et al., Eur. J. Biochem., 249, 2016-2031 (2002)). TFPI is a 43 kDa serine protease inhibitor comprising three Kunitz-type inhibitory domains (Figure 2). Kunitz domain I of TFPI binds FVIIa and Kunitz domain 2 binds FXa, enabling the inhibitor to form a quaternary FXa-TFPI-FVIIa-TF complex that blocks activity of the TF/FVIIa extrinsic complex (Figure 3). TFPI binding of FXa also downregulates the common pathway of the coagulation cascade, during which FXa converts prothrombin to thrombin (Audu et al., Anesth. Analg., 103(4), 841-845 (2006)). The invention provides, e.g., TFPI-inhibitory peptides that block TFPI's inhibitory action on the blood coagulation cascade, thereby enhancing thrombin formation. [0035] The amino acid sequences of several TFPI-binding peptides are provided herein. Conventional amino acids are identified according to their standard, one-letter or three-letter codes, as set forth in Table 1. TABLE 1 3-letter I-letter Amino acids 3-letter 1-letter Amino acids codes code codes code Ala A Alanine Met M Methionine Cys C Cysteine Asn N Asparagine Asp D Aspartic acid Pro P Proline Glu E Glutamic acid Gin Q Glutamine Phe F Phenylalanine Arg R Arginine Gly G Glycine Ser S Serine 11 His H Histidine Thr T Threonine Ile I Isoleucine Val V Valine Lys K Lysine Trp W Tryptophan Leu L Leucine Tyr Y Tyrosine [00361 Non-conventional amino acids and additional peptide building blocks are identified according to a three-letter code (with the exception of Ttds, which is a common four-letter abbreviation) found in Table 2. TABLE 2 Name Abbreviation Structure 2-aminobutyric acid Abu

H

2 N -OH 2-Amino-isobutyric acid Aib

H

2 N OH Bal 0 NH 2 Q-Alanine HO j-Homoglutamatic acid Bhe HO 0

H

2 N {S) OH OM 1 J12 Name Abbreviation Structure $-Homophenylalanine Bhf HO P-Homolysine Bhk

H

2 N OH

NH

2 0 $-Homoleucine Bhl OH

NH

2 P-Homoasparagine Bhn H2N H2N HO f-Homoglutamine Bhq NH2

NH

2 OH P-Homoarginine Bhr NH N NH (6) NH NH S-Homoserine Bhs HO

NH

2 OH P-Homotyrosine Bhy HO

NH

2 13 Name Abbreviation Structure f-Homoaspartic acid Bhd OH H0 0

NH

2 B-Homovaline Bhv, Btl NH2

H

2 0 OH p3-Homoasparagin Bhn, Btq 0 NH 2 O

H

2 N OH (S)-Cyclohexylalanine Cha H OH (S)-Citmllin Cit HO H--0-NH 0 NH 2

H

2 N (S)-2,4-Diaminobutyric acid Dab

H

2 % OH

H

2 N (S)-Diaminopropionic acid Dap

H

2 N S

H

2 N OH (S)-2-Propargylglycine Eag

H

2 N OH 14 Name Abbreviation Structure (S)-N(omega)-nitro-arginine Eew 0 0 HN N+ HO N NH NH2 L-homophenylalanine Hfe

H

2 N HO O (S)-Homo-arginine Har NHH _ H2 HN O OH (S)-Homo-citr-ulline Hei H NH OHN HH

NH

2 (S)-2-Amino-5-methyl-hexanoic Hle acid 0 NH 2 (S)-Homo-lysine Hly HO 0 15 Name Abbreviation Structure (S)-Norleucine Nie HO

H

2 N (S)-N-Methylalanine Nma HOH (S)-N-Methyl-Aspartic acid Nmd O OH 0 O HO N (S)-N-Methyl-glutamic acid Nme 0 HO 0 N OH H (S)-N-Methyl-phenylalanine Nmf H HO 0 N-Methyl-glycine Nmg HN 0 (S)-N-Methyl-lysine Nmk 0 OHNH N N H 2 H (S)-N-Methyl-leucine NmO 16 Name Abbreviation Structure (S)-N-Methyl-arginine Nmr 0:Or NH 2 N N H (S)-N-Methyl-serine Nms HO 0 Cs H NH /H (S)-N-Methyl-valine Nmv OH NH (S)-N-Methyl- tyro sine Nmy 0 HN OiH (S)-2-Amino-pentanoic acid Nva H2N 0 OH (S)-2-Pyridyl-alanine Opa N INs OH

H

2 N (S)-Ornithine Orn OH

H

2 N 0 NH, L-phenylglycin Phg

H

2 N OH 17 Name JAbbreviation Structure 4-Phenyl-butyric acid PhPrCO OH Polyethylene glycol PEG Selenomethionine Sem 0 Se OH

NH

2 1,2,3,4-L- Tic tetrahydroisoquinolinecarboxylic acid OH ~NH (13-Amino-4,7, 10-trioxa- Ttds tridecayl)-succinamic acid H H Carboxyfluorescein FAM O0) OH (Z) 0 0 HO [0037] The amino acid sequences of the peptides provided herein are depicted in typical peptide sequence format, as would be understood by the ordinary skilled artisan. For example, the three-letter code or one-letter code of a conventional amino acid, or the three letter code or abbreviation for a non-conventional amino acid, indicates the presence of the amino acid in a specified position within the peptide sequence. The code for each non 18 conventional amino acid is connected to the code for the next and/or previous amino acid in the sequence by a hyphen. Adjacent amino acids are connected by a chemical bond (typically an amide bond). The formation of the chemical bond removes a hydroxyl group from the 1 carboxyl group of the amino acid when it is located to the left of the adjacent amino acid (e.g., Hle-adjacent amino acid), and removes a hydrogen from the amino group of the amino acid when it is located on the right of the adjacent amino acid (e.g., adjacent amino acid-Hle). It is understood that both modifications can apply to the same amino acid and apply to adjacent conventional amino acids present in amino acid sequences without hyphens explicitly illustrated. Where an amino acid contains more than one amino and/or carboxy group in the amino acid side chain, the 2- or 3-amino group and/or the 1-carboxy group generally are used for the formation of peptide bonds. For non-conventional amino acids, a 3-letter code was used where the first letter indicates the stereochemistry of the C-a-atom. For example, a capital first letter indicates that the L-form of the amino acid is present in the peptide sequence, while a lower case first letter indicating that the D-form of the correspondent amino acid is present in the peptide sequence. When one-letter code is used, a lower case letter represents a D-amino acid, while an upper case letter represents an L-amino acid. Unless indicated to the contrary, the amino acid sequences are presented herein in N- to C-terminus direction. [0038] The C-termini of several TFPI-binding peptide sequences described herein are explicitly illustrated by inclusion of an OH, NH 2 , or an abbreviation for a specific terminating amine linked to the C-terminal amino acid code via a hyphen. The N-termini of several peptides described herein are explicitly illustrated by inclusion of a hydrogen (for a free N terminus), or an abbreviation for a specific terminating carboxylic acid or other chemical group linked to the N-terminal amino acid code via a hyphen. [0039] The invention provides a peptide comprising the amino acid sequence

X

7

XSX

9 XiX X 12

X

1 3

X

14

X

1 5

X

1 6

X

1 7XssX9X2OX2I (SEQ ID NO: 3109), wherein (using single letter codes for amino acids)

X

7 is selected from the group consisting of L, P, K, S, W, V, N, and Q;

X

8 is selected from the group consisting of L, R, N, F, and I;

X

9 is selected from the group consisting of Y, V, P, and C; Xio is selected from the group consisting of F, L, and G; Xrj is selected from the group consisting of L, W, V, A, M, T, and S;

X

12 is selected from the group consisting of T, F, V, R, A, D, L, E, S, and Y;

X,

3 is selected from the group consisting of I, M, G, Q, D, and R; 19

X

14 is selected from the group consisting of G, W, Y, L, M, and H;

X

15 is selected from the group consisting of N, P, F, H, K, and Y;

X

16 is selected from the group consisting of M, D, E, V, G, and K;

X

17 is selected from the group consisting of G, I, R, S, T, and L; Xis is selected from the group consisting of M, K, L, and I;

X

19 is selected from the group consisting of Y, G, R, and S;

X

20 is selected from the group consisting of A, E, S, C, and Y; and

X

2 1 is selected from the group consisting of A, V, K, and E. [0040] In addition to the core structure set forth above, X 7

-X

21 , other structures that are specifically contemplated are those in which one or more additional amino acids are attached to the core structure (e.g., linked to the N-terminus or the C-terminus of the amino acid sequence X 7

-X

21 ). Thus, the invention includes peptides comprising the core structure and further comprising one or more N-terminal amino acid(s) comprising an amino acid sequence selected from the group consisting of:

X

6 , X5X6,

X

4

X

5 X6,

X

3

X

4

X

5

X

6 (SEQ ID NO: 3110),

X

2

X

3

X

4

X

5

X

6 (SEQ ID NO: 3111), and

X

1

X

2

X

3

X

4

X

5

X

6 (SEQ ID NO: 3112); wherein X 6 is directly linked to X 7 of the core structure amino acid sequence, and X is selected from the group consisting of T and G;

X

2 is selected from the group consisting of F and V;

X

3 is selected from the group consisting of V, W, Y, and F;

X

4 is selected from the group consisting of D, Q, and S;

X

5 is selected from the group consisting of E, T, N, and S; and

X

6 is selected from the group consisting of R, H, K, and A. The peptide of the invention in one aspect comprises or consists of the amino acid sequence QSKKNVFVFGYFERLRAK (SEQ ID NO: 1). [0041] In another embodiment, the peptide of the invention comprising the core structure comprises one or more C-terminal amino acid(s) comprising an amino acid sequence selected from the group consisting of:

X

22 ,

X

2 xn 23 , 20

X

22

X

23

X

2 4 , X22X23X 2 4

X

2 5 (SEQ ID NO: 3113),

X

2 2

X

2 3 X24X 2 5

X

26 (SEQ ID NO: 3114), and

X

2 2

X

2 3 X2 4

X

2 5

X

26

X

27 (SEQ ID NO: 3115), wherein X 22 is directly linked to X, 1 of the core structure amino acid sequence, and X22 is selected from the group consisting of Q, 1, E, W, R, L, and N;

X

23 is selected from the group consisting of L, V. M, and R;

X

2 4 is selected from the group consisting of K, L, A, and Y;

X

25 is F;

X

2 6 is G; and

X

2 7 is T. [0042] In one aspect, the peptide of the invention comprises or consists of the amino acid sequence VIVFTFRHNKLIGYERRY (SEQ ID NO: 4). It is also contemplated that the peptide of the invention comprises additional amino acids at both the N-terminus and the C terminus of the core structure. In this aspect, the peptide comprises or consists of the amino acid sequence TFVDERLLYFLTIGNMGMYAAQLKF (SEQ ID NO: 3), GVWQTHPRYFWTMWPDIKGEVIVLFGT (SEQ ID NO: 5), KWFCGMRDMKGTMSCVWVKF (SEQ ID NO: 6)., or ASFPLAVQLHVSKRSKEMA (SEQ ID NO: 7). [00431 The invention further includes peptides comprising the amino acid sequence

X

3

X

4

X-F-X

7

-NVF-X

1 iXI 2 -GY-XiX 6

-RLRAK-X

2 2 (SEQ ID NO: 2), wherein X 3 is Y or F;

X

4 is Q or S; X 5 is N or S; X7 is K, N, or Q; X 11 is V, A, S, or T; X 12 is F, A, D, L, Q, S, or Y;

X

15 is F, K, or Y; X 1 6 is E or D; and X 22 is L or N. [0044] In addition, the invention provides a peptide that binds TFPI, wherein the peptide comprises the structure of formula (I): X1001-X1002-XI003-X]004-X1005-X1006-X1007 X1,008-X1009-XO1O-XIO1-X1012-X1013-X1014-XI015-X1016-X1017-X1018-XIO19 X1020 (SEQ ID NO: 3116). In formula (I), X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y; X1002 is an amino acid selected from the group consisting of G, K and Q; X1003 is an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, L K. L, M, N, P, Q, R, S, T, V,W and Y; 21 X1004 is an amino acid selected from the group consisting of, A, Aib, Bhk., C, D, E. F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y; X1005 is an amino acid selected from the group consisting of a, A, Aib. Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y; X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F. G, H, I, K, L, M, N, Q, R, S T, V, W and Y; X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L,. Nmv. P, Q, S, V, W and Y; X1008 is an amino acid selected from the group consisting of F. H, K, W and Y; X1009 is an amino acid selected from the group consisting of A, Aib, f, 1, K, S. T and V; X1OlO is an amino acid selected from the group consisting of A, Aib, C, D, E, F, G, H, 1, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y; XIO11 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg; X1012 is Y; X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y; X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; X1015 is an amino acid selected from the group consisting of (omega-methyl)-R, D, E, K and R; X1016 is L; X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, D. Dab, Dap, E, Eag, Eew., F, G, H, Har, Hci, Hie, I, K, L, M, N, Nie, Nva, Opa, Orn, Q, R, S, T, V, W and Y; X1OI 8 is an amino acid selected from the group consisting of A, Bal, C, D, E, F. G, H, I, K, L, M, N, Q, R, S, T, V, W and Y; and X1019 is an amino acid selected from the group consisting of Bhk, K, R and V. X1020 is either present or absent in formula (1) (i.e., in some instances, the peptide of the invention comprises the structure X100] -X1002-X 1003-XI004-X1005-X1006-X1007 22 X1008-XI010-XO11-X1012-X1013-X1014-X1015-X1016-X1017-X1O18-X1019 (SEQ ID NO: 3116)). When X1020 is present, it is an amino acid selected from the group consisting of Aib, Bhl, C, F. G, H, I, K, L, Nml, Q, R, S, T, V, W and Y. [0045] For example, the peptide of the invention comprises the structure of formula (I) wherein X1001 is an amino acid selected from the group consisting of C, F, 1, K, L, Nmf, V. M, W and Y; X1002 is Q; X1003 is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V; X1004 is an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y; X1005 is an amino acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y; X1006 is an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y; X1007 is an amino acid selected from the group consisting of I, K. L, Q, V and Y; X1008 is an amino acid selected from the group consisting of F, H and Y; X1009 is an amino acid selected from the group consisting of f, I and V; X1010 is an amino acid selected frm the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y; X101 1 is an amino acid selected from the group consisting of G and Nmg; X1012 is Y; X1013 is an amino acid selected from the group consisting of Aib, C, F, H, L, W and Y; X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K. L, M, N, Q, R, S, T, V, W and Y; X1015 is an amino acid selected from the group consisting of E and R; X1016 is L; X1017 is an amino acid selected from the group consisting of (omega-rmethyl)-R, A, Aib, Bhr, C, Cha, Cit. Dab, Dap, Eag, Eew, F, H, Har, Hci, Hie, I, K, L, M, N, Nie, Nva, Opa, Orn, R, S, T, V and Y; X10 18 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W; X1019 is an amino acid selected from the group consisting of K and R; and X1020 is an amino acid selected from the group consisting of Aib, Bhl, F, K, L, R and W (when X1020 is present in the peptide). [0046] In one aspect, the peptide of the invention comprises the structure of formula (I) wherein X1001 is an amino acid selected from the group consisting of F, L, Y and M; X1002 is Q; X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C; X1004 is an amino acid selected from the group consisting of Aib, K, L, P. R, E, G, I, Y, M and W; X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M; X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M; X1007 is an amino acid selected from the group consisting of I and V; X1008 is an amino acid selected from the group consisting of F, H and Y; X1009 is V; X1010 is an amino acid selected from the group consisting of A, D, E, K. M, 23 N, Q, R, F, H, P, S, V, W and Y; X1011 is G; X1012 is Y; X1013 is C or F; X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib; X1015 is R; X1016 is L; X1017 is an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M; X1018 is an amino acid selected from the group consisting of A, L, N, M and R; X1019 is K; and X1020 is K or L. [0047] When amino acid X 1020 is absent from formula (I), the peptide of the invention in one aspect further comprises amino acid X1000 at the N-terminus of formula (I), such that the peptide comprises or consists of the structure of formula (11): X1000-X1001-X1002 X1003-X1004-X1005-XI006-X1007-X1O08-X1009-XlO1-X1011-X1012-X1013-X1014 X1015-X1016-X1017-XI018-X1019 (I) (SEQ ID NO: 3122). When X1000 is present in the peptide, X1000 is an amino acid selected from the group consisting of A, E, and P, while the amino acids of X1001-X 1019 are as defined above. [0048] In an additional aspect, the TFPI-binding peptide of the invention comprises the structure of formula (I1): X1001-Q-XI003-XI004-X1005-XI006-I/V-XI008-V-X1010-G Y-C/F-X1014-R-L-X017-XIO18-K-K/L (III) (SEQ ID NO: 3117). X1001, X1003, X1004, X1005, X1006. X1008, X1010, X1014, X1017 and X101 8 in formula (III) are each independently selected from any amino acid. For example, in formula (111), X1001 is optionally an amino acid selected from the group consisting of Bhf, C, D, F, G, H, 1, K, L, M, N, Nmf, Q, R, T, V,W and Y, such as an amino acid selected from the group consisting of C, F, 1, K, L, Nmf, V, M, W and Y (e.g., an amino acid selected from the group consisting of F, L, Y and M); X1003 is optionally an amino acid selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,W and Y, such as an amino acid selected from the group consisting of A, C, D, E, H, K, M, I. N, Q, R, S, T and V (e.g., the amino acid is M, Q, R, S, T or C); X1004 is optionally an amino acid selected from the group consisting of, A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Aib, C. D, E, G, H, F, 1, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y (e.g., an amino acid selected from the group consisting of Aib, K. L, P, R, E, G, 1, Y, M and W); X1005 is optionally an amino acid selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T, V, W and Y, such as an amino 24 acid selected from the group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, T and Y (e.g., the amino acid is a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C or M); X1006 is optionally an amino acid selected from the group consisting of A, Aib, Btq, C. D, E, F, G, H, 1, K, L, M, N, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y (e.g., an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M); X1008 is optionally an amino acid selected from the group consisting of F, H, K, W and Y, such as an amino acid selected from the group consisting of F, H and Y; X1010 is optionally an amino acid selected from the group consisting of A, Aib, C, D, E, F, G. H, I, K, L, M, N, Nmf. P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, D, E, F, G, H, K, L. M, N, P, Q, R, S, T, V. W and Y (e.g., an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R. F, H, P, S, V. W and Y); X1014 is optionally an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, 1, K, L, M, N, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, Aib, Rhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y (e.g., A, C, D, E. K, L, M, N, Q, R, T, V or Aib); X1017 is optionally an amino acid selected from the group consisting of (omega methyl)-R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hie, I, K, L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Orn, R, S, T, V and Y (e.g., an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nie, Nva, Opa, Orn, R, I, L, S and M); and/or X1018 is optionally an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, 1, K, L, M, N, Q, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, C, D, E, F, 1, K. L, M, N, Q, R, V and W (e.g., an amino acid selected from the group consisting of A, L, N, M and R). [0049] In some embodiments, the peptide of the invention comprises one or more additional amino acid residues attached to the N- or C-terminus of the amino acid sequence. For example, the peptide comprising the structure of any one of formulas (l)-(III), in some embodiments, further comprises one or more N-terminal amino acid(s) directly linked to 25 X1001, wherein the N-terminal amino acid(s) comprise the amino acid sequence selected from the group consisting of X1000, X999-X1000, X998-X999-XI000, X997-X998-X999-X1000 (SEQ ID NO: 3123), X996-X997-X998-X999-X1000 (SEQ ID NO: 3124), X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125), X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3126), X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127), X992-X993-X994-X995-X996-X997-X998-X999-XIOOO (SEQ ID NO: 3128), X991.-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3129), and X990-X991 -X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3130). When the peptide comprises one or more N-terminal amino acids, X1000 is A or K; X999 is V or K; X998 is Q or K; X997 is L or K; X996 is R or K; X995 is G or K; X994 is V or K; X993 is G or K; X992 is S or K; X991 is K; and X990 is K. [0050] In addition to the core structures set forth in formulas (l)-(I1I), other structures that are specifically contemplated are those in which one or more additional amino acids are attached to the C-terminus of the core structure directly linked to X1020. For example, the C-terminal addition optionally comprises an amino acid sequence selected from the group consisting of X1021, X1021-X1022, X1021-X1022-X1023, and X1021-XI022-X1023 X1024 (SEQ ID NO: 3131), wherein X1021 is T or K; X1022 is S or K; and X1023 and X1024 are K. [0051] The invention further includes a TFPI-binding peptide comprising or consisting of an amino acid sequence having at least 60% identity (e.g., at least 65%, at least 70%, at least 75%. at least 80%, at least 85%, at least 90%, at least 95 % or 100% identity) to the amino acid sequence Ac-FQSK-Nmg-NVFVDGYFERL-Aib-AKL-NH2 (formula IV) (SEQ ID NO: 164). In some instances, the peptide comprises or consists of the amino acid sequence of any one of formulas (1)-(III), as described herein. The invention also includes a peptide 26 comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-978 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 8-741 and 962-972 (such as SEQ ID NOs: 8-741, 962-968, 971, or 972) and/or selected fiom the group consisting of 742-961 (such as SEQ ID NOs: 744-961) and/or selected from the group consisting of SEQ ID NOs: 973-978). [00521 The peptides of the invention, in some instances, comprise intramolecular disulfide bonds. In this regard, the peptide comprising the structure of formulas (I)-(III) contains at least two cysteine residues (e.g., the peptide contains two cysteine residues) that are spaced apart by at least three amino acid residues such that the cysteines form an intramolecular disulfide bond. In some instances, the cysteines are spaced apart by more than three amino acid residues. For example, in the peptide comprising the structure of formulas (I), (II), or (III), any two of X1000, X1001, X1003, X1004, X1005, X1006., X1010. X1011, X1013, X1014, X1017, X101 8, X1020 and X1021 are optionally cysteines capable of forming a disulfide bridge. Accordingly, in some aspects, the peptide contains two cysteine residues: one of X1000, X1005, X1010 and X1014 is cysteine, and one of X1006, X1010, X1017 and X1021 is a cysteine. The invention contemplates all of the possible combinations of cysteine pairs, e.g., X1000 and X1006 are C; X1000 and X1010 are C; X1000 and X1017 are C; X1005 and X1017 are C; X1010 and X1017 are C; X1010 and X1021 are C; or X1014 and X1021 are C. [0053] The invention further provides a peptide that binds TFPI, the peptide comprising the structure of formula (V): X2001 -X2002-X2003-X2004-X2005-X2006-[X2007-X2008 X2009-X2010-X2011 -X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020 X2021-X2022-X2023 (V) (SEQ ID NO: 3118), wherein the peptide forms a cyclic structure generated by a linkage, e.g., a disulfide bond, between X2007 and X2018 (denoted as brackets within formula (V)). In formula (V),. X2001, X2002, and X2023 are independently either present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W; X2002 an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W; and X2023 is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, S, T. V, W and Y. In addition, X2003 is an amino acid selected from the group consisting of A, F, 1, K, L, R, S, T, V, W and Y; 27 X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W; X2005 is W; X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W; X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K (e.g., C or Hey); X2008 is an amino acid selected from the group consisting of A, G, R, S and T; X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem, and V; X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P. R, S, T and V; X2011 is an amino acid selected from the group consisting of D, E, G, S, and T; X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L. 1, M, m, Nle, nie, P, p, R, r, S, s, Sem, T, t, V, v, W and w; X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W; X2014 is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, M, R, S, T, V and W; X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K. L, M, Nle, R, S, T, V and W; X2016 is an amino acid selected from the group consisting of A, D, E, F, 1, K, L, M, Nle, R, S, Sem, T, V, W and Y; X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y; X2018 is an amino acid selected from the group consisting of C and D (e.g., X2018 is C); X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W; X2020 is an amino acid selected from the group consisting of F and W; 28 X2021 is an amino acid selected from the group consisting of I, L and V; and X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W. [0054] In some instances, in the peptide of the invention comprising the structure of formula (V), X2001 is optionally an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L and S (when X2001 is present).; X2002 is optionally an amino acid selected from the group consisting of A, D, F, G, H, K, L, P, R and S, such as an amino acid selected from the group consisting of A, F, H, K, L, M, R and S (e.g., H, F, M or R) (when X2002 is present); X2003 is optionally an amino acid selected from the group consisting of A, F, K, L, S and Y, such as an amino acid selected from the group consisting of F, S and Y (e.g., F or Y); X2004 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L and S (e.g., K); X2005 is optionally W; X2006 is optionally an amino acid selected from the group consisting of F, H, K and L (e.g., F or H); X2007 is optionally an amino acid selected from the group consisting of C and HcY (e.g., X2007 is C); X2008 is optionally an amino acid selected from the group consisting of A., G and S; X2009 is optionally an amino acid selected from the group consisting of a, A, K, L, V, M, m, Ne, Sem, and p, such as an amino acid selected from the group consisting of M, Nle, p and V (e.g., M, Sem, or V); X2010 is optionally an amino acid selected from the group consisting of A, G, K, L, P, R and S, such as an amino acid selected from the group consisting of A, K, L, P, R and S (e.g., K, P, or R); X2011 is optionally an amino acid selected from the group consisting of D. G and S (e.g., D or S); X2012 is optionally an amino acid selected from the group consisting of A, a, D, d, F. f, G, K, k, L, 1, M, n, Nie, P. S and s, such as an amino acid selected from the group 29 consisting of D, d, F, f, G, K, k, L, 1, M, Nie, P, S, and Sem (e.g., an amino acid selected from the group consisting of F, L, 1, Sem, and M); X2013 is optionally an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s, such as an amino acid selected from the group consisting of A, D, F, G, K, L and S (e.g., D, G, K, or S); X2014 is optionally an amino acid selected from the group consisting of D, F, G, K, L and S (e.g., D or G); X2015 is optionally an amino acid selected from the group consisting of A, D, F, G, I, K, L, M, Nie. S and T (e.g., I or T); X2016 is optionally an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, and Y, such as an amino acid selected from the group consisting of D, F, K. L, M, Nle, S, Sem, and Y (e.g., D, F, M, Sem, or Y); X2017 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, S, T and Y (e.g., S or T); X2018 is optionally C; X2019 is optionally an amino acid selected from the group consisting of A, F, L, S and V (e.g., A or V); X2020 is optionally an amino acid selected from the group consisting of F and W (e.g., W); X2021 is optionally an amino acid selected from the group consisting of L and V (e.g., V); X2022 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W, such as an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W (e.g., an amino acid selected from the group consisting of F, L, K, R, P and W); and X2023 is optionally an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y, such as an amino acid selected from the group consisting of A, D. F, G, L M, S and Y (e.g., an amino acid sequence selected from the group consisting of A, D, F, M, S and Y) (when X2023 is present). [0055] The invention further includes a peptide that binds TFPI, wherein the peptide comprises the structure of formula (VI): X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V 30 X2010-D-X2012-X2013-G-IT-X2016-S/T-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119). In the peptide comprising the structure of formula (VI), X2001, X2002 and X2023 are each independently present or absent. If X2001, X2002, and/or X2023 are present, any of X2001, X2002 and X2023 is independently selected from any amino acid. In addition, X2008, X2010, X2012, X2013, X2016, and X2022 are each independently selected from any amino acid. [0056] In some aspects, in the peptide of formula (VI), X2001 is optionally an amino acid selected from the group consisting of A, D, E, F. G, H, I, K, L, P, R, S, T, V and W, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S (e.g., an amino acid selected from the group consisting of A, D, F, G, H, K, L and S) (when X2001 is present); X2002 is optionally an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W, such as an amino acid selected from the group consisting of A, D, F, G, H, K, L, M, P, R and S (e.g., an amino acid selected from the group consisting of A, F, H, K, L, M, R and S, such as H, F, M, or R) (when X2002 is present); X2008 is optionally an amino acid selected from the group consisting of A, G, R, S and T, such as an amino acid selected from the group consisting of A, G and S; X2010 is optionally an amino acid selected from the group consisting of A, G, 1, K, L, P, R, S, T and V, such as an amino acid selected from the group consisting of A, G, K, L, P, R and S (e.g., an amino acid selected from the group consisting of A, K, L, P, R and S, such as K, P or R); X2012 is optionally an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, I, K, k, L, 1, M, m, Me. nie, P, p, R, r, S, s, Sem, T, t, V, v , W and w, such as an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, 1, M, m, Nie, P, S, s, and Sem (e.g., an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, 1, M. Ne, P, S, and Sem, such as F, L, 1, Sem, or M); X2013 is optionally an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W, such as an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s (e.g., an amino acid selected from the group consisting of A, D, F, G, K, L and S, such as D, G, K or S); X2016 is optionally an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y, such as an amino acid selected from the group 31 consisting of D, F, K, L, M, Nle, S Sem, and Y (e.g., an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem, such as F, Sem, or M); X2022 is optionally an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W, such as an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W (e.g., an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W, such as F. L, K, R, P or W); and/or X2023 is optionally an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, M, S, T, V, W and Y, such as an amino acid selected from the group consisting of A, D, F, G, K., L, M, S and Y (e.g., an amino acid selected from the group consisting of A, D, F, G, L M, S and Y, such as A, D, F, M, S or Y) (when X2023 is present). [0057] The TFPI-binding peptide of the invention, in one aspect, comprises an amino acid sequence having at least 60% identity (e.g., at least 60%, at least 65%, at least 70%. at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% identity) to the sequence of formula VII: Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH2 (VII) (SEQ ID NO: 1040). Optionally, the peptide comprises or consists of the amino acid sequence of formula (V)-(VII) as defined herein. The invention also includes a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1293 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1212 and 1290-1291 (such as SEQ ID NOs: 1001-120, 1290, or 1291) and/or selected from the group consisting of SEQ ID NOs: 1213-1289 and/or selected from the group consisting of 1292 and 1293). [0058] The invention further provides a TFPI-binding peptide comprising the structure of formula (VIII): X300I-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010 X30 11 -X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In formula (VIII), X3001 and X3002 are independently either present or absent in the peptide. If present, X3001 is an amino acid selected from the group consisting of A, C, D. F, G, 1, K, L, M, N, P, Q, R, S, T, W, E, H and Y; and X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L. In addition, X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, 1, K, L, M, N, P. Q, R, S, T, W and Y; X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G. H, 1, K, L, M, N, Q, R, S, T, V, W, Y and P; 32 X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R. S, T. V, W and Y; X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H; X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S. T. W and Y; X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W. Y and I; X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K; X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H; X3012 is an amino acid selected from the group consisting of A, C, H, I, K. L and R; X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I; X3014 is an amino acid selected from the group consisting of A, C, F, G, H, , L, M, N, Q, R, S, T, V, W, Y and K; X3015 is an amino acid selected from the group consisting of A, K and R; X3016 is an amino acid selected from the group consisting of A, F, K and R; X3017 is an amino acid selected from the group consisting of A, C, F, G, 1 K, L, N, Q, R, S, T, V, W, Y, H, A and M; X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y; X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I; X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N. Q. R, V, W, Y, I and P; and X3021 is an amino acid selected from the group consisting of A, C, H, 1, K, L, M. N, P, Q, R, T, V, W, Y, F and G. 33 [0059] In some aspects of the invention, the peptide comprises the sequence of formula (VIII), wherein X3001 is optionally an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y, such as an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y (when X3001 is present); X3002 is optionally an amino selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L, such as an amino acid selected from the group consisting of C, K, R, W, Y. G, I and L (when X3002 is present); X3003 is optionally an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W, such as an amino acid selected from the group consisting of A, C, G, H, 1, K, L, M, R, S, T and W; X3004 is optionally an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N. R. S, T, V and P, such as an amino acid selected from the group consisting of A, C. G, H, I, K, L, M, N, R, S, T and P; X3005 is optionally an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y, such as an amino acid selected from the group consisting of C, F. H, K, R and W; X3006 is optionally an amino acid selected from the group consisting of P, H and A; X3007 is optionally an amino acid selected from the group consisting of C, G, R, W, A and L, such as an amino acid selected from the group consisting of L, C, R and W; X3008 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I, such as an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I; X3009 is optionally an amino acid selected from the group consisting of C, 1, R, V and K, such as an amino acid selected from the group consisting of C, R, V and K; X3010 is optionally an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R,. S and T, such as an amino acid selected from the group consisting of A, C, K, L, Q, R and S; X3011 is optionally an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H, such as an amino acid selected from the group consisting of 1, K, L, M, R, V, W, C, F and H; 34 X3012 is optionally an amino acid selected from the group consisting of H and R (e.g., H); X3013 is optionally an amino acid selected from the group consisting of C, F, K, L, M, R, V and I, such as an amino acid selected from the group consisting of C, K, R, V and I; X3014 is optionally an amino acid selected from the group consisting of A, M, C, F, H, 1, L, N, R, S, V, W and K, such as an amino acid selected from the group consisting of A, S, C, F, H, I, R and K; X3015 is optionally K or R; X3016 is optionally K or R; X3017 is optionally an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M, such as an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M; X3018 is optionally an amino acid selected from the group consisting of A, K, C, I, L, R and W (e.g., K, C, 1, R, or W); X3019 is optionally an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I, such as an amino acid selected from the group consisting of C, E, H, K, R and I; X3020 is optionally an amino acid selected from the group consisting of C, H, L, M, R, V, I and P (e.g.. C, M, I, or P); and X3021 is optionally an amino acid selected from the group consisting of A, C, H, 1, K, L, M, N, Q, R, V, W, Y, F and G, such as an amino acid selected from the group consisting of A, C, H, 1, K, L, M, N, Q, R, V, W, F and G. [00601 The invention further provides a peptide that binds TFPI and comprises the structure of formula (IX): X3001 -X3002-X3003-X3004-X3005-X3006-X3007-X3008 X3009-X3010-X301 I -H-X3013-X3014-K/R-R-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ TD NO: 3121). In formula (IX), X3001 and X3002 are independently either present or absent in the peptide. If present, X3001 and/or X3002 are independently selected from any amino acid. Likewise, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X30 11, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. When present, X3001 is optionally an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y, such as an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q. R, S, 35 T. W, E, H and Y (e.g., an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y). Likewise, when present, X3002 is optionally an amino acid selected from the group consisting of A, C, D, F, H. K, M, N, P, R, S, T, W, Y, G, I and L, such as an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L (e.g., an amino acid selected from. the group consisting of C, K, R, W, Y, G, I and L). Also with respect to formula (IX), X3003 is optionally an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, and Y, such as an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W (e.g., an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W); X3004 is optionally an amino acid selected from the group consisting of A, C, D, E, F, 6, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P, such as an amino acid selected from the group consisting of A, C, D, G, H, 1, K, L, M, N. R, S, T, V and P (e.g., an amino acid selected from the group consisting of A, C. G, H, I, K, L, M, N, R, S, T and P); X3005 is optionally an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y, such as an amino acid selected from the group consisting of C, F, H, I, K, M, R, T, W and Y (e.g., an amino acid selected from the group consisting of C, F, H, K, R and W); X3006 is optionally an amino acid selected from the group consisting of A, W, C, K, P, R and H, such as an amino acid selected from the group consisting of P, H and A; X3007 is optionally an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y, such as an amino acid selected from the group consisting of C, G, R, W, A and L (e.g., L, C, R or W); X3008 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I, such as an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I (e.g., an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I); X3009 is optionally an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K, such as an amino acid selected from the group consisting of C, I, R, V and K (e.g., C, R, V or K); X301 0 is optionally an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, such as an amino acid selected from the group 36 consisting of A, C, G, H, I, K, L, M, Q, R, S and T (e.g., an amino acid selected from the group consisting of A, C, K, L, Q, R and S); X3011 is optionally an amino acid selected from the group consisting of A, G, 1, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H, such as an amino acid selected from the group consisting of A, 1, K, L, M, R, S, V, W, C, F and H (e.g., an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H); X3013 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and 1, such as an amino acid selected from the group consisting of C, F, K, L, M, R, V, and I (e.g., C, K, R, V, or I); X3014 is optionally an amino acid selected from the group consisting of A, C, F, G, H, 1, L, M, N. Q, R, S, T, V, W. Y and K, such as an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K (e.g., an amino acid selected from the group consisting of A, S, C, F, H, 1, R and K); X3017 is optionally an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S. T, V, W, Y, H, A and M, such as an amino acid selected from the group consisting of A, C, F, G, 1, K, L, N, Q, R. S, T, V, W, H, A and M (e.g., an amino acid selected from the group consisting of C, G,1 , K, L, N, Q, R, S, T, V, H, A and M); X3018 is optionally an amino acid selected from the group consisting of A, C, F, 1, K, L, M, Q, R. V, W and Y, such as an amino acid selected from the group consisting of A, K, C, I, L, R and W (e.g., K, C, I, R, or W); X3019 is optionally an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I, such as an amino acid selected from the group consisting of A, C., E, H, K, N, Q, R and I (e.g., C, E, H, K, R, or I); X3020 is optionally an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P, such as an amino acid selected from the group consisting of C, H, L, M, R, V, I and P (e.g., C, M, I, or P); and/or X3021 is optionally an amino acid selected from the group consisting of A, C, H, 1, K, L, M, N, P, Q, R, T, V. W, Y, F and G, such as an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q. R, V, W, Y, F and G (e.g., an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G). [0061] The TFPI-binding peptide of the invention comprises, in some aspects, an amino acid sequence having at least 60% identity (e.g., at least 65%, at least 70%, at least 75%, at 37 least 80%, at least 85%, at least 90%, at least 95% or 100% identity) to the sequence of formula (X): Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (X) (SEQ ID NO: 223). Optionally, the peptide comprises or consists of the amino acid sequence of formula (VIII) (IX) as defined herein. As used herein, "at least 60% identity" and similar terms encompass any integer from, e.g., 60%, to 100%, such as 60%, 61%, 62%, and the like. Also, the term "at least [percentage] identity" encompasses any percentage that is greater than or equal to the number of identical amino acids divided by the total number of amino acids of the peptide of the invention ([at least percentage identity] > [number of identical amino acids] / [total number of amino acids of the peptide of the invention]). [0062] The invention also includes a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2498 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2296 and 2498 (such as SEQ ID NOs: 2001-2126, 2128-2296, or 2498) and/or selected from the group consisting of SEQ ID NOs: 2297-2497 (such as SEQ ID NOs: 2298-2497)). The invention further provides a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3108 (e.g., a peptide comprising or consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3064 (such as SEQ ID NOs: 3001-3048, 3051-3053, 3055, or 3057-3064) and/or selected from the group consisting of SEQ ID NOs: 3065-3084 (such as SEQ ID NOs: 3066-3084) and/or selected from the group consisting of SEQ ID NOs: 3085-3108). [0063] The peptide of SEQ ID NOs: 1-7 also, in some aspects, comprises one or more amino acids attached at the N- or C-terminus of SEQ ID NOs: 1-7. For example, the invention includes a peptide comprising or consisting of the amino acid sequence of JBT0047, JBT0051, JBT0055, JBT0I31, JBT0132, JBT0133, JBTOI55, JBT0I58, JBT0162, JBT0163, JBTOI64, JBT066, JBT0169, JBTO170, JBT0171, JBT0174, JBT0175, or JBT0293, all of which comprise the amino acid sequence of SEQ ID NO: 1. Exemplary peptides comprising the amino acid sequence of SEQ ID NO: 2 include peptides comprising or consisting of the amino acid sequence of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBT0302, JBT0303, JBTO304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, or JBTO311. Exemplary peptides comprising the amino acid sequence of SEQ ID NO: 3 comprise or consist of the amino acid sequence of JBT0049, JBT0053, JBT0057, JBT0190, JBT0193, or JBT0197. The invention further includes a peptide comprising or consisting of the amino acid sequence of JBT0050, JBT0054, JBT0058, JBT01 29, JBT0I 30, JBT0205, JBTO208, JBT021 1, JBT0212, JBT0217, 38 JBTO2 18, or JBT0219, all of which include the amino acid sequence of SEQ ID NO: 4. Exemplary peptides comprising SEQ ID NO: 5 include those comprising or consisting of the amino acid sequence of JBT0101, JBT0052, JBT0103, JBT0178, or JBT0182, The invention additionally includes a peptide comprising or consisting of the amino acid sequence of JBT0120, JBT0124. JBT0247, JBT0248, JBT0251, or JBT0252, each of which include the amino acid sequence of SEQ ID NO: 6. A peptide including the amino acid sequence of SEQ ID NO: 7, e.g., a peptide comprising or consisting of the amino acid sequence of JBT0l 22, JBT0126. JBT0221, JBT0224, JBT0225, JBT0226, JBT0228, JBT0232, or JBT0233, also provided by the invention. The peptides described herein are set forth in Table 5 of Example 1 and in Figures 12-18. [0064] In certain embodiments, the peptide of the invention comprises or consists of the amino acid sequence of JBT0047, JBT0049, JBT01 01, JBT01 20, or JBT0122 or any of the inventive peptides described herein (e.g., a peptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1-3108, such as a peptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 8-741, 744-968, 971-978, 1001-1210, 1213-1289, 1290-1293, 2001-2126, 2128-2296, 2298-2498, 3001-3048, 3051-3053, 3055, 3057-3064, and 3067-3108), or a variant of any of the foregoing. By "variant" is meant a peptide comprising one or more amino acid substitutions, amino acid deletions, or amino acid additions to a parent amino acid sequence. Variants include, but are not limited to, peptides having an amino acid sequence that is at least 60%, 65%, 70%, 71%, 72%, 73%, 74%. 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any of the amino acid sequences provided herein while retaining the ability to bind TFPI and/or inhibit TFPI activity. In one embodiment, the peptide comprises or consists of the amino acid sequence of JBT0132, JBT0303, JBT0193, JBT0178, JBT0120, or JBT0224. [0065] In one aspect, the peptide of the invention consists of 40 amino acids or less, such as 35 amino acids or less. Optionally, the peptide of the invention consists of 25 amino acids or less, or 10 amino acids or less. In various embodiments, the peptide comprises 15-35 amino acid residues (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 amino acid residues). However, it is also contemplated that a peptide described herein comprising one or more deletions is suitable in the context of the invention so long as the peptide blocks TFPI inhibition of the coagulation cascade and, optionally, binds TFPI. In one aspect, the peptide comprising one or more deletions is suitable in the context of the invention so long as the peptide binds TFPI and, optionally, blocks TFPI inhibition of the 39 coagulation cascade. In some aspects, amino acids are removed from within the amino acid sequence, at the N-terminus, and/or at the C-terminus. Such peptide fragments can comprise 3-14 amino acid residues (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid residues). [0066] Optionally, the peptide of the invention comprises one or more amino acid substitutions (with reference to any of the amino acid sequences provided herein) that do not destroy the ability of the peptide to bind and/or inhibit TFPI. For instance, peptides comprising or consisting of the amino acid sequence selected from the group consisting of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBTO302, JBT0303, JBT0304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, or JBT0311 are substitutional mutants of the amino acid sequence of JBT0293 (the amino acid sequence of SEQ ID NO: 1 directly linked to a phenylalanine residue at the N-terminus and a lysine reside at the C-terminus) (see Figure 4). Amino acid substitutions include, but are not limited to, those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinities, and/or (4) confer or modify other physiochemical or functional properties on a peptide. In one aspect, the substitution is a conservative substitution, wherein an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art, and include amino acids with basic side chains (e.g,, lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine., serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), beta-branched side chains (e.g., threonine, valine, and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). It will be appreciated, however, that a practitioner is not limited to creating conservative substitutions so long as the resulting peptide retains the ability to downregulate, in whole or in part, TFPI activity. The invention also embraces TFPI-inhibitoiy peptides comprising atypical, non-naturally occurring amino acids, which are well known in the art. Exemplary non-naturally occurring amino acids include omithine, citrulline, hydroxyproline, homoserine, phenylglycine, taurine, iodotyrosine, 2,4-diaminobutyic acid, a-amino isobutyric acid, 4-aminobutyric acid, 2-amino butyric acid, y-amino butyric acid, 2-amino isobutyric acid, 3-amino propionic acid, norleucine, norvaline, sarcosine, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, j-alanine, a fluoro-amino acid, a 3-methyl amino acid, a-C-methyl amino acid, a N-methyl amino acid, 2 amino-isobutyric acid, p-homoglutamatic acid, P-homophenylalanine, p-homolysine, 0 40 homoleucine, P-homoasparagine, 5-homoglutanine, -homoarginine, $-homoserine, f homotyrosine, f-homoaspaitic acid, $-homovaline, $-homoasparagin. (S)-cyclohexylalanine, (S)-citrullin, (S)-2,4-diaminobutyric acid, (S)-2,4-diaminobutyric acid, (S)-diaminopropionic acid, (S)-2-propargylglycine, (S)-N(omega)-nitro-arginine, L-homophenylalanine, S)-horno arginine, (S)-homo-citrulline, (S)-homo-cysteine, (S)-2-amino-5-methyl-hexanoic acid, (S) homo-lysine, (S)-norleucine, (S)-N-methylalanine, (S)-N-methyl-aspartic acid, (S)-N-methyl glutamic acid, (S)-N-methyl-phenylalanine, N-methyl-glycine, (S)-N-methyl-lysine, (S)-N methyl-leucine, (S)-N-methyl-arginine, (S)-N-methyl-serine., (S)-N-methyl-valine, (S)-N methyl-tyrosine, (S)-2-amino-pentanoic acid, (S)-2-pyridyl-alanine, (S)-ornithine, L phenylglycin, 4-phenyl-butyric acid and selenomethionine. The individual amino acids may have either L or D stereochemistry when appropriate, although the L stereochemistry is typically employed for all of the amino acids in the peptide. [00671 The invention further includes TFPI-inhibitory peptide variants comprising one or more amino acids inserted within an amino acid sequence provided herein and/or attached to the N-terminus or C-terminus. In one aspect, the peptide further comprises one or more amino acids that facilitate synthesis, handling, or use of the peptide, including, but not limited to, one or two lysines at the N-terminus and/or C-terminus to increase solubility of the peptide. Suitable fusion proteins include, but are not limited to, proteins comprising a TFPI inhibitory peptide linked to one or more polypeptides, polypeptide fragments, or amino acids not generally recognized to be part of the protein sequence. In one aspect, a fusion peptide comprises the entire amino acid sequences of two or more peptides or, alternatively, comprises portions (fragments) of two or more peptides. In addition to all or part of the TFPI-inhibitory peptides described herein, a fusion protein optionally includes all or part of any suitable peptide comprising a desired biological activity/function. Indeed, in some aspects, a TFPI-inhibitory peptide is operably linked to, for instance, one or more of the following: a peptide with long circulating half life, a marker protein, a peptide that facilitates purification of the TFPI-inhibitory peptide, a peptide sequence that promotes formation of multimeric proteins, or a fragment of any of the foregoing. In one embodiment, two or more TFPI-inhibitory peptides are fused together, linked by a multimerization domain, or attached via chemical linkage to generate a TFPI-inhibitory peptide complex. The TFPI-inhibitor peptides may be the same or different. [0068] "Derivatives" are included in the invention and include TFPI-inhibitory peptides that have been chemically modified in some manner distinct from addition, deletion, or substitution of amino acids. In this regard, a peptide of the invention provided herein is 41 chemically bonded with polymers, lipids, other organic moieties, and/or inorganic moieties. Examples of peptide and protein modifications are given in Hermanson, Bioconjugate Techniques, Academic Press, (1996). Derivatives are prepared in some situations to increase solubility, stability, absorption, or circulating half-life. Various chemical modifications eliminate or attenuate any undesirable side effect of the agent. In this regard, the invention includes TFPI-inhibitory peptides covalently modified to include one or more water soluble polymer attachments. Useful polymers known in the art include, but are not limited to, polyethylene glycol (PEG) (e.g., PEG approximately 40 kD or I kD in size), polyoxyethylene glycol, polypropylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures of any of the foregoing. In one aspect, the peptide of the invention is a PEGylated peptide. For further discussion of water soluble polymer attachments, see U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; and 4,179,337. In another aspect, a peptide derivative includes a targeting moiety specific for a particular cell type, tissue, and/or organ. Alternatively, the peptide is linked to one or more chemical moieties that facilitate purification, detection, multimerization, and characterization of peptide activity. An exemplary chemical moiety is biotin. In addition, in one aspect, the peptides of the invention are acylated at the N-terminal amino acid of the peptide. In another aspect, the peptides of the invention are amidated at the C-terminal amino acid of the peptide. In a still further aspect, the peptides of the invention are acylated at the N-terminal amino acid of the peptide and are amidated at the C-terminal amino acid of the peptide. [0069] Derivatives also include peptides comprising modified or non-proteinogenic amino acids or a modified linker group (see, e.g., Grant, Synthetic Peptides: A User's Guide. Oxford University Press (1992)). Modified amino acids include, for example, amino acids wherein the amino and/or carboxyl group is replaced by another group. Non-limiting examples include modified am-ino acids incorporating thioamides, ureas, thioureas, acylhydrazides, esters, olefines, sulfonamides, phosphoric acid amides, ketones, alcohols, boronic acid amides, benzodiazepines and other aromatic or non-aromatic heterocycles (see Estiarte et al., Burgers Medicinal Chemisnty, 6th edition, Volume 1, Part 4, John Wiley & Sons, New York (2002)). Modified amino acids are often connected to the peptide with at least one of the above mentioned functional groups instead of an amide bond. Non-proteinogenic amino acids include, but are not limited, to 0-alanine (Bal), norvaline (Nva), norleucine (Nle), 4 aminobutyric acid (y-Abu), 2-aminoisobutyric acid (Aib), 6-aminohexanoic acid (s-Ahx)., 42 ornithine (Orn), hydroxyproline (Hyp), taurine, sarcosine, citrulline (Cit), cysteic acid (Coh), cyclohexylalanine (Cha), methioninesulfoxide (Meo), methioninesulfone (Moo), homoserinemethylester (Hsm), propargyiglycine (Eag), 5-fluorotryptophan (5Fw), 6 fluorotryptophan (6Fw), 3',4'-dimethoxyphenyl-alanine (Ear), 3',4'-difluorophenylalanine (Dff), 4'-fluorophenyl-alanine (Pff), 1-naphthyl-alanine (iNi), 1-methyltryptophan (lMw), penicillamine (Pen), homoserine (Hse), t-butylglycine, t-butylalanine, phenylglycine (Phg), benzothienylalanine (Bta), L-homo-cysteine (Hey), N-methyl-phenylalanine (Nmf), 2 thienylalanine (Thi), 3,3-diphenylalanine (Ebw), homophenylatanine (Hfe) and S-benzyl-L cysteine (Ece). These and other non-proteinogenic amino acids may exist as D- or L isomers. Examples of modified linkers include, but are not limited to, the flexible linker 4,7,10-trioxa- 1,1 3-tridecanediamine (Ttds), glycine, 6-aminohexanoic acid, beta-alanine (Bal), and combinations of Ttds, glycine, 6-aminohexanoic acid and Bal. [0070] Homologues of the amino acids constituting the peptides of the invention may be as set forth in Table 3. TABLE3 Amino Acid Exemplary homologues A Aib, Bat, Eag, Nma, Abu, G, M, Nva, Ne C S. A, Hey, M, L, I, V, Nme, P-Cysteine D E, Homoglutamic acid, y-Hydroxy-glutamic acid, 7-Carboxy glutamic acid, Nmd, P-Aspartic acid, N, Q, Cysteic acid E D, Glu, Homoglutamic acid, y-Hydroxy-glutamic acid, y-Carboxy glutamic acid, ax-Aminoadipic acid, Nme, P-glutamic acid, Q, N, Cysteic acid F Hfe, Nmf, p-Phenylalanine, Phg, Bhf, Thienylalanine, Benzothienylalanine, Bromophenylalanine, lodophenylalanione, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, Y, W, Naphtylalanine, Tic G A, Nmg H Nmh, I -Methylhistidine, 3-Methylhistidine, Thienylalanine I L, V, Hle. Nva, Nle, @-Isoleucine, Nml, M, Nmi 43 K Nmk, R, Nmr, S-Lysine, Dab, Dap, J-(1-Piperazinyl)-alanine, 2,6 Diamino-4-hexynoic acid, delta-Hydroxy-lysine, Har, omega Hydroxy-norarginine, omega-Amino-arginine, omega-Methyl arginine, J-(2-Pyridyl)-alanine, f-(3-Pyridyl)-alanine, 3-Amino tyrosine, 4-Amino-phenylalanine, Hci. Cit L 1, V, Hie, Nle, Nva, f-Isoleucine. Nml, M M 1, V, Hie, Nva, R, Har, Nmm, Methioninesulfone N Nmn, f-Asparagine, Q, Nmq, S-Glutamine, Cys(3-propionic acid amide)-OH, Cys(02-3-propionic acid amide)-OH P Azetidine-2-carboxylic acid, Hyp, a-Methyl-methionine, 4 Hydroxy-piperidine-2-carboxylic acid, Pip, a-Methyl-Pro Q N, Nmn, Nmq, $-Glutamine, Cys(3-propionic acid amide)-OH, Cys(02-3-propionic acid amide)-OH R Nmk, K, Nmr, f-Lysine, Dab, Dap, Orn, f-(1-Piperazinyl)-alanine, 2,6-Diamino-4-hexynoic acid, delta-Hydroxy-lysine, Har, omega Hydroxy-norarginine, omega-Amino-arginine, omega-Methyl arginine, S-(2-Pyridyl)-alanine, -(3-Pyridyl)-alanine, 3-Amino tyrosine, 4-Amino-phenylalanine, Hci, Cit, Hie, L, Nie, M S T, Hse, S-Serine, C, f-Cyano-alanine, allo-Threonine T S, Homothreonine, $-Threonine, allo-Threonine v L, I, Hle, Nva, Nle, $.-Valine, Nmv, M, Nmi, Nml W Nmw, 0-Tryptophan, F, Hfe, Nmf, B-Phenylalanine, Phg, Bhf, Thienylalanine, Benzotbienylalanine, Biomophenylalanine, lodophenylalanine, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, Y, Naphtylalanine, Tic Y Nmy, $-Tyrosine, , F, Hfe, Nmf, -Phenylalanine, Phg, Bhf, Thienylalanine, Benzothienylalanine, Bromophenylalanine, lodophenylalanine, Chlorophenylalanine, Methylphenylalanine, Nitrophenylalanine, W, Naphtylalanine, Tic 44 [0071] In some embodiments, the peptide (CO-NH) linkages joining amino acids within the peptide of the invention are reversed to create a "retro-modified" peptide, i.e., a peptide comprising amino acid residues assembled in the opposite direction (NH-CO bonds) compared to the reference peptide. The retro-modified peptide comprises the same amino acid chirality as the reference peptide. An "inverso-modified" peptide is a peptide of the invention comprising amino acid residues assembled in the same direction as a reference peptide, but the chirality of the amino acids is inverted. Thus, where the reference peptide comprises L-amino acids, the "inverso-modified" peptide comprises D-amino acids, and vice versa. Inverso-modified peptides comprise CO-NH peptide bonds. A "retro-inverso modified" peptide refers to a peptide comprising amino acid residues assembled in the opposite direction and which have inverted chirality. A retro-inverso analogue has reversed termini and reversed direction of peptide bonds (i.e., NH-CO), while approximately maintaining the side chain topology found in the reference peptide. Retro-inverso peptidonimetics are made using standard methods, including the methods described in Meziere et al, J. Immunol., 159, 3230-3237 (1997), incorporated herein by reference. Partial retro-inverso peptides are peptides in which only part of the amino acid sequence is reversed and replaced with enantiomeric amino acid residues. [0072] TFPI-binding peptides of the invention (e.g., TFPI inhibitor peptides) are made in a variety of ways. In one aspect, the peptides are synthesized by solid phase synthesis techniques including those described in Merrifield, J. Am. Chem. Soc., 85, 2149 (1963); Davis et al., Biochem. Intl., 10, 394-414 (1985); Larsen et al., J. Am. Chem. Soc., 115, 6247 (1993); Smith et al., J. Peptide Protein Res., 44, 183 (1994); O'Donnell et al., J. Am. Chem. Soc., 118, 6070 (1996); Stewart and Young, Solid Phase Peptide Synthesis, Freeman (1969); Finn et al., The Proteins, 3rd ed., vol. 2, pp. 105-253 (1976); and Erickson et al., The Proteins, 3rd ed., vol. 2, pp. 257-527 (1976). Alternatively, the TFPI-binding peptide (e.g., the TFPI-inhibitory peptide) is expressed recombinantly by introducing a nucleic acid encoding a TFPI-binding peptide (e.g., a TFPI-inhibitory peptide) into host cells, which are cultured to express the peptide. Such peptides are purified from the cell culture using standard protein purification techniques. [0073] The invention also encompasses a nucleic acid comprising a nucleic acid sequence encoding a TFPI-inhibitory peptide of the invention. Methods of preparing DNA and/or RNA molecules are well known in the art. In one aspect, a DNA/RNA molecule encoding a peptide provided herein is generated using chemical synthesis techniques and/or using polymerase chain reaction (PCR). If desired, a TFPI-inhibitory peptide coding sequence is 45 incorporated into an expression vector. One of ordinary skill in the art will appreciate that any of a number of expression vectors known in the art are suitable in the context of the invention, such as, but not limited to, plasmids, plasmid-liposome complexes, and viral vectors. Any of these expression vectors are prepared using standard recombinant DNA techniques described in, e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994). Optionally, the nucleic acid is operably linked to one or more regulatory sequences, such as a promoter, activator, enhancer, cap signal, polyadenylation signal, or other signal involved with the control of transcription or translation. [0074] Any of the TFPI-inhibitory peptides of the invention or nucleic acids encoding the peptides also is provided in a composition (e.g., a pharmaceutical composition). In this regard, the peptide is formulated with a physiologically-acceptable (i.e., pharmacologically acceptable) carrier, buffer, excipient, or diluent, as described further herein. Optionally, the peptide is in the form of a physiologically acceptable salt, which is encompassed by the invention. "Physiologically acceptable salts" means any salts that are pharmaceutically acceptable. Some examples of appropriate salts include acetate, hydrochloride, hydrobromide, sulfate, citrate, tartrate, glycolate, and oxalate. If desired, the composition comprises one or more additional pharmaceutically-effective agents. [00751 The peptide provided herein optionally inhibits at least one Tissue Factor Pathway Inhibitor-I (e.g., TFPI-la) activity such as, but not limited to, an activity that downregulates the blood coagulation cascade. Without being bound by any specific mechanism of action, a proposed mechanism of inhibition may involve preventing formation of the quaternary TF FVIIA-FXA-TFPI complex. The peptide may inhibit binding of TFPI to FXa (e.g., inhibit binding of TFPI Kunitz domain 2 to Factor Xa), the TF/FVIIa complex (e.g., inhibit binding of TFPL Kunitz domain 1 to the TF/FVIIa complex), TF alone, and/or FVIa alone, With TFPI activity diminished, TF and FVIIa are free to activate FX which, in turn, enhances conversion of prothrombin to thrombin. [0076] In one aspect, the peptide of the invention exhibits TFPI antagonistic activity in model and/or plasmatic systems. An exemplary model system for determining TFPI inhibitory activity is the extrinsic tenase assay, which tests the ability of candidate peptides to restore extrinsic complex-mediated FX activation in the presence of TFPI (which is a natural inhibitor of the FX activation reaction) (see, e.g., Lindhout et al., Thromb, Haemost., 74, 910 915 (1995)). Another model system for characterizing TFPI-inhibitory activity is the FXa 46 inhibition assay, wherein FXa activity is measured in the presence of TFPI (see Sprecher et al., PNAS, 91, 3353-3357 (1994)). The extrinsic tenase assay and the FXa inhibition assay are further described in Example 3. Optionally, the peptide of the invention enhances FX activation in the presence of TFPI with a half maximal effective concentration (EC 50 ) of less than or equal to I x 104 M, less than or equal to ] x 10- M, less than or equal to 1 x 10 6 " M. or less than or equal to I x 10-7 M. [0077] In one aspect, TFPI-antagonist activity is characterized in a plasma-based assay. Thrombin formation is triggered in plasma substantially lacking FVIII or FIX activity (e.g., the residual coagulation factor activity is lower than 1%) in the presence of a candidate peptide. Thrombin formation can be detected using a fluorogenic or chromogenic substrate, as described in Example 4. A system for measuring thrombin activity is provided by Thrombinoscope BV (Maastricht, The Netherlands). Prothrombin conversion is measured using, e.g., a ThrombographTM (Thermo Scientific, Waltham, MA), and the resulting data is compiled into a Calibrated Automatic Thrombogram generated by ThrombinoscopeTM software available from Thrombinoscope BV. In certain embodiments, the TFPI-inhibitory peptide increases the amount of peak thrombin generated during the assay and/or decreases the time required to achieve peak thrombin formation. For example, the peptide improves TFPI-regulated thrombin generation in the absence of FVIII (e.g., in FVIII-depleted plasma) to at least 1% of the level of TFPI-dependent thrombin generation in normal plasma. Generally, normal (unafflicted) plasma contains about 0.5 U/mL to about 2 U/mL Factor VIH. Accordingly, in some instances, a TFPI-inhibitor peptide will enhance thrombin formation in the absence of FVIII to at least about 1% of that observed in the presence of 0.5 U/mL to 2 U/mL FVIII. In further embodiments, the peptide enhances thrombin formation in the absence of Factor VIII to at least about 2%, at least about 3%, at least about 5%, at least about 7%, or at least about 10% of the level of thrombin formation in normal plasma, i.e., in the presence of physiological levels of Factor VIII. In various aspects, the peptide is administered to an animal model of thrombin deficiency or hemophilia to characterize TFPI inhibitory activity in vivo. Such in vivo models are known in the art and include for example, mice administered anti-FVII antibodies to induce hemophilia A (Tranholm et al., Blood, 102, 3615-3620 (2003)); coagulation factor knock-out models such as, but not limited to, FVIII knock-out mice (Bi et al., Nat. Genet., 10(1), 119-121 (1995)) and FIX knock-out mice (Wang et al., PNAS, 94(21), 11563-66 (1997)); induced hemophilia-A in rabbits (Shen et al., Blood, 42(4), 509-521 (1973)); and Chapel Hill HA dogs (Lozier et al., PNAS, 99, 12991 12996 (2002)). 47 [0078] While not being bound to any particular theory or mechanism, the peptide of the invention provided herein may inhibit TFPI activity by blocking (competitively or allosterically) binding of TFPI and FXa. Alternatively or in addition, the peptide may inhibit binding of TFPI with a Tissue Factor (TF)/Factor VIla complex. Thus, in certain aspects, the peptide specifically binds TFPL. Various peptides bind TFP1 from any source including, but not limited to, mouse, rat, rabbit, dog, cat, cow, horse, pig, guinea pig, and primate. In one embodiment, the peptide binds human TFPL Optionally, the TFPI-inhibitory peptide binds TFPI from more than one species (i.e., the peptide is cross-reactive among multiple species). In certain aspects, the peptide binds TFPI with a dissociation constant (KD) of less than or equal to 1 x 10- 4 M, less than or equal to 1 x 10 5 M, less than or equal to 1 x 10-6 M, or less than or equal to I x 10-7 M. Affinity may be determined using, for example and without limitation, any one, two, or more of a variety of techniques, such as affinity ELISA assay, a competitive ELISA assay, and/or surface plasmon resonance (BIAcoreTM) assay. When characterized using a competitive (IC 5 o) ELISA assay, the peptide of the invention optionally demonstrates an IC 5 o of less than or equal to about 50,000 nM. For example, the peptide demonstrates an ICso of less than or equal to about 10,000 nM, such as an IC 5 0 of less than or equal to about 5,000 nM, less than or equal to about 1,000 nM, or less than or equal to about 500 nM. In one aspect, the peptide demonstrates an IC 5 0 of less than or equal to about 250 nM, less than or equal to about 100 nM, or less than or equal to about 50 nM. Exemplary peptides and their IC 5 o values are provided in Figures 32-39; in some instances, the peptides are classified into Groups A, B, C, D, E, F, and G (see Table 4 in Example 1) based on their

IC

50 values. In various aspects, the invention provides peptides falling within Groups A, B, C, D, E, F, and/or 0 as defined in Table 4. Affinity may also be determined by a kinetic method or an equilibrium/solution method. Such methods are described in further detail herein or known in the art. [0079] As with all binding agents and binding assays, one of skill in the ait recognizes that the various moieties to which a binding agent should not detectably bind in order to be biologically (e.g., therapeutically) effective would be exhaustive and impractical to list. Therefore, the term "specifically binds" refers to the ability of a peptide to bind TFPI with greater affinity than it binds to an unrelated control protein that is not TFPI. For example, the peptide may bind to TFP1 with an affinity that is at least, 5, 10, 15, 25, 50, 100, 250, 500, 1000, or 10,000 times greater than the affinity for a control protein. In some embodiments, the peptide binds TFPI with greater affinity than it binds to an "anti-target," a protein or other naturally occurring substance in humans to which binding of the peptide might lead to 48 adverse effects. Several classes of peptides or proteins are potential anti-targets. Because TFPI-inhibitory peptides exert their activity in the blood stream and/or at the endothelium, plasma proteins represent potential anti-targets. Proteins containing Kunitz domains (KDs) are potential anti-targets because KDs of different proteins share a significant similarity. Tissue Factor Pathway Inhibitor-2 (TFPI-2) is highly similar to TFPI-l a and, like TFPI-Ia, contains KDs (Sprecher et al., PNAS, 91, 3353-3357 (1994)). Thus, in one aspect, the peptide of the invention binds to TFPI with an affinity that is at least 5, 10, 15, 25, or 50 times greater than the affinity for an anti-target, such as TFPI-2. [00801 The invention further includes a method of inhibiting Tissue Factor Pathway Inhibitor-I (TFPI). The method comprises contacting TFPI with a TFPI-binding peptide as described herein. Any degree of TFPI-activity inhibition is contemplated. For example, a TFPI-inhibitory peptide reduces TFPI-inhibition of the extrinsic pathway at least about 5% (e.g., at least about 10%, at least about 25%, or at least about 30%). In some embodiments, the TFPI-inhibitory peptide reduces TFPI activity within the extrinsic pathway at least about 50%, at least about 75%, or at least about 90% compared to TFPI activity in the absence of the peptide. [00811 The invention further includes a method for targeting biological structures (including, but not limited to, cell surfaces and endothelial lining) where TFPI is located. The method comprises contacting the biological structure (e.g., including, without limitation, a cell displaying TFPI on the cell surface) with a TFPI-binding peptide described herein, optionally conjugated to a moiety that adds additional functionality to the peptide. The moiety can be a dye (such as a fluorescence dye), a radionuclide or a radionuclide-containing complex, a protein (e.g., an enzyme, a toxin, or an antibody) or a cytotoxic agent. For example, the peptide is linked or conjugated to an effector moiety that facilitates peptide detection and/or purification and/or comprises therapeutic properties. In one aspect, the TFPI-binding peptide or peptide conjugate is administered to a mammal to target a TFPI displaying cell within the mammal. Optionally, the method further comprises detecting binding of the TFPI-binding peptide to TFPI. The method is useful for therapy and diagnostic of disease where TFPI is a suitable diagnostic marker or TFPI-expressing cells are a target for a therapeutic approach. [0082] In some aspects, peptide-TFPI binding is detected indirectly. In this regard, the peptide is contacted with an interaction partner that binds the peptide of invention without significantly interfering with peptide-TFPI binding, and the interaction partner is detected. Exemplary interaction partners include, but are not limited to, antibodies, antigen-binding 49 antibody fragments, anticalins and antibody mimetics, aptamers, and spiegelmers. Optionally, the interaction partner comprises a detection moiety to facilitate detection of an interaction partner-peptide complex. Methods of detecting, e.g., antibodies and fragments thereof, are well understood in the art. Similarly, detection moieties are widely used in the art to identify biological substances and include, for example, dye (e.g., fluorescent dye), radionuclides and radionuclide-containing complexes, and enzymes. [00831 Thus, the invention provides a method for diagnosing a subject suffering from a disease or disorder, or at risk of suffering from a disease or disorder, wherein the disease or disorder is associated with or caused by aberrant TFPI activity. The method comprises administering to the subject the TFPI-binding peptide of the invention and detecting the TFPI-peptide complex. In some instances, the peptide of the invention is conjugated to a detectable moiety, and the method comprises detecting the detectable moiety. In other instances, the method comprises administering to the subject a TFPI-binding peptide interaction partner that binds the TFPI-binding peptide, and detecting the interaction partner. If desired, the interaction partner comprises or is conjugated to a detectable moiety, and the detectable moiety is detected. The presence of the detectable moiety indicates the presence of TFPI, thereby allowing diagnosis of a disease or disorder associated with TFPI (e.g., a disease or disorder which (i) can be treated by inhibiting TFPI or (ii) comprises symptoms which can be ameliorated or prevented by inhibiting TFPI). If administration of the peptide to the subject is not desired, a biological sample is obtained from the subject, contacted with the TFPI-binding peptide as described herein, and TFPI-peptide complexes are detected. [0084] The peptides of the invention bind TFPI and, therefore, are useful for purifying TFPI or recombinant TFPI from a biological sample (e.g., a biological fluid, such as serum), fermentation extract, tissue preparations, culture medium, and the like. The invention includes methods of using the TFPI-binding in the commercial production of TFPI or in a method of characterizing TFPI molecules. For example, the invention includes a method of purifying TFPI. The method comprises contacting a sample containing TFPI with a peptide as defined herein under conditions appropriate to form a complex between TFPI and the peptide; removing the complex from the sample; and, optionally, dissociating the complex to release TFPl. Exemplary conditions appropriate to form a complex between TFPI and the peptide are disclosed in the Examples, and such conditions can be easily modified to dissociate the TFPI-peptide complex. In some embodiments, the peptide is immobilized to a support, e.g., a solid support, to facilitate recovery of TFPI. For example, in one embodiment, the peptide is immobilized to chromatography stationary phase (e.g., silica, 50 affinity chromatography beads, or chromatography resins), a sample comprising TFPI is applied to the stationary phase such that TFPI-peptide complexes are formed, the remainder of the sample is removed from the stationary phase, and TFPI is eluted from the stationary phase. In this regard, the peptides of the invention are, in one aspect, suitable for use in affinity chromatography techniques. [0085] A method of enhancing thrombin formation in a clotting factor-deficient subject also is provided. The method comprises administering to the subject a peptide provided herein under conditions effective to inhibit TFPI. In this regard, the TFPI-inhibitory peptide is administered in an amount and under conditions effective to enhance thrombin formation in the subject. By "clotting factor-deficient" is meant that the subject suffers from a deficiency in one or more blood factors required for thrombin formation, such as FVILL FIX, or FXI. Indeed, in one embodiment, the subject is deficient in FVII. Alternatively or in addition, the subject is deficient in Factor IX. Clotting factor deficiencies are identified by examining the amount of factor in a clinical sample. Practitioners classify hemophilia according to the magnitude of clotting factor deficiency. Subjects suffering from mild hemophilia have approximately 5% to 30% of the normal amount (I U/ml) of Factor VIII or Factor IX. Moderate hemophilia is characterized by approximately I % to 5% of normal Factor Vill, Factor IX, or Factor XI levels, while subjects suffering from severe hemophilia have less than 1% of the normal amount of Factor VIII, Factor IX, or Factor XI. Deficiencies can be identified indirectly by activated partial thromboplastin time (APTT) testing. APTT testing measures the length of time required for a blood clot to form, which is longer for patients with Factor VIII Deficiency (hemophilia A), Factor IX Deficiency (hemophilia B), and Factor XI Deficiency (hemophilia C) compared to patients with normal clotting factor levels. Almost 100% of patients with severe and moderate Factor VIII deficiency can be diagnosed with an APTT. The invention further includes enhancing thrombin formation in a subject that does not suffer from a clotting factor deficiency. The method comprises administering to a subject (e.g., a subject comprising normal, physiological levels of clotting factor) a peptide provided herein under conditions effective to enhance thrombin formation. [0086] In one aspect, the TFPI-inbibitory peptide is used for increasing blood clot formation in a subject. The method of increasing blood clot formation comprises administering to the subject a peptide described herein in an amount and under conditions effective to increase blood clot formation. It will be appreciated that the method need not completely restore the coagulation cascade to achieve a beneficial (e.g., therapeutic) effect. Any enhancement or increase in thrombin or blood clot formation that reduces the onset or 51 severity of symptoms associated with clotting factor deficiencies is contemplated. Methods of determining the efficacy of the method in promoting thrombin formation and blood clotting are known in the art and described herein. [0087] The invention further includes a method of treating a blood coagulation disorder in a subject, the method comprising administering to the subject one or more TFPl-inhibitory peptides, such as any one or more of the peptides described herein, in an amount and under conditions effective to treat the blood coagulation disorder in the subject. In one aspect, the peptide is not a naturally-occurring peptide that inhibits TFPI activity. "Coagulation disorders" include bleeding disorders caused by deficient blood coagulation factor activity and deficient platelet activity. Blood coagulation factors include, but are not limited to, Factor V (FV), FVII, FVIII, FIX, FX, FXI, FXLI FII (responsible for hypoprothrombinemia), and von Willebrand's factor. Factor deficiencies are caused by, for instance, a shortened in vivo-half-life of the factor, altered binding properties of the factor, genetic defects of the factor, and a reduced plasma concentration of the factor. Coagulation disorders can be congenital or acquired. Potential genetic defects include deletions, additions and/or substitution within a nucleotide sequence encoding a clotting factor whose absence, presence, and/or substitution, respectively, has a negative impact on the clotting factor's activity. Coagulation disorders also stem from development of inhibitors or autoimmunity (e.g., antibodies) against clotting factors. In one example, the coagulation disorder is hemophilia A. Alternatively, the coagulation disorder is hemophilia B or hemophilia C. [0088] Platelet disorders are caused by deficient platelet function or abnormally low platelet number in circulation. Low platelet count may be due to, for instance, underproduction, platelet sequestration, or uncontrolled patent destruction, Thrombocytopenia (platelet deficiencies) may be present for various reasons, including chemotherapy and other drug therapy, radiation therapy, surgery, accidental blood loss, and other disease conditions. Exemplary disease conditions that involve thrombocytopenia are: aplastic anemia; idiopathic or immune thrombocytopenia (ITP), including idiopathic thrombocytopenic purpura associated with breast cancer; HIV-associated ITP and HIV related thrombotic thrombocytopenic purpura; metastatic tumors which result in thrombocytopenia; systemic lupus erythematosus, including neonatal lupus syndrome splenomegaly; Fanconi's syndrome; vitamin B12 deficiency; folic acid deficiency; May Hegglin anomaly; Wiskott-Aldrich syndrome; chronic liver disease; myelodysplastic syndrome associated with thrombocytopenia; paroxysmal nocturnal hemoglobinuria; acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy; alloimmune 52 thrombocytopenia, including maternal alloimmune thrombocytopenia; thrombocytopenia associated with antiphospholipid antibodies and thrombosis; autoimmune thrombocytopenia; drug-induced immune thrombocytopenia, including carboplatin-induced thrombocytopenia and heparin-induced thrombocytopenia; fetal thrombocytopenia; gestational thrombocytopenia; Hughes' syndrome; lupoid thrombocytopenia; accidental and/or massive blood loss; myeloproliferative disorders; thrombocytopenia in patients with malignancies; thrombotic thrombocytopenia purpura, including thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in cancer patients; post transfusion purpura (PTP); autoimmune hemolytic anemia; occult jejunal diverticulum perforation; pure red cell aplasia; autoimmune thrombocytopenia; nephropathia epidemica; rifampicin-associated acute renal failure; Paris-Trousseau thrombocytopenia; neonatal alloimmune thrombocytopenia; paroxysmal nocturnal hemoglobinuria; hematologic changes in stomach cancer; hemolytic uremic syndromes (e.g., uremic conditions in childhood); and hematologic manifestations related to viral infection including hepatitis A virus and CMV associated thrombocytopenia. Platelet disorders also include, but are not limited to, Von Willebrand Disease, paraneoplastic platelet dysfunction, Glanzman's thrombasthenia, and Bernard-Soulier disease. Additional bleeding disorders amenable to treatment with a TFPI inhibitory peptide include, but are not limited to, hemorrhagic conditions induced by trauma; a deficiency in one or more contact factors, such as FXI, FXII, prekallikrein, and high molecular weight kininogen (HMWK); vitamin K deficiency; a fibrinogen disorder, including afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia; and alpha2-antiplasmin deficiency. In one embodiment, the TFPI-inhibitory peptide is used to treat excessive bleeding, such as excessive bleeding caused by surgery, trauma, intracerebral hemorrhage, liver disease, renal disease, thrombocytopenia, platelet dysfunction, hematomas, internal hemorrhage, hemarthroses, hypothermia, menstruation, pregnancy, and Dengue hemorrhagic fever. All of the above are considered "blood coagulation disorders" in the context of the disclosure. [0089] In one aspect, the TFPI-inhibitory peptide of the invention is used to reverse the effects (in whole or in part) of one or more anticoagulants in a subject. Numerous anticoagulants are known in the art and include, for instance, heparin; cournarin derivatives, such as warfarin or dicumarol; TFPI; AT III; lupus anticoagulant; nematode anticoagulant peptide (NAPc2); FVIIa inhibitors: active-site blocked FVIIa (FVIlai); active-site blocked FIXa (FIXai); FIXa inhibitors; FXa inhibitors, including fondaparinux, idraparinux, DX 9065a, and razaxaban (DPC906); active-site blocked FXa (FXai); inhibitors of FVa or 53 FVmIa. including activated protein C (APC) and soluble thrombomodulin; thrombin inhibitors, including hirudin, bivalirudin, argatroban, and ximelagatran; and antibodies or antibody fragments that bind a clotting factor (e.g., FV, FVII, FVIII, FIX, FX, FXIH, FII, FXI, FXII, von Willebrand factor, prekallikrein, or high molecular weight kininogen (HMWK)). [0090] As used herein, "treating" and "treatment" refers to any reduction in the severity and/or onset of symptoms associated with a blood coagulation disorder. Accordingly, "treating" and "treatment" includes therapeutic and prophylactic measures. One of ordinary skill in the art will appreciate that any degree of protection from, or amelioration of, a blood coagulation disorder or symptom associated therewith is beneficial to a subject, such as a human patient. The quality of life of a patient is improved by reducing to any degree the severity of symptoms in a subject and/or delaying the appearance of symptoms. Accordingly, the method in one aspect is performed as soon as possible after it has been determined that a subject is at risk for developing a blood coagulation disorder (e.g., a deficiency in a clotting factor (e.g., FVIII, FIX, or FXI) is detected) or as soon as possible after a blood coagulation disorder (e.g., hemophilia A, hemophilia B, or hemophilia C) is detected. In an additional aspect, the peptide is administered to protect, in whole or in part, against excessive blood loss during injury or surgery. [0091] In view of the above, the invention provides a peptide for use in a method for the treatment of a subject, such as a method for the treatment of a disease where the inhibition of TFPI is beneficial. In one aspect, the disease or disorder is a blood coagulation disorder. The subject is suffering from a disease or disorder or is at risk from suffering from a disease or disorder (or adverse biological event, such as excessive blood loss). The method comprises administering to the subject the peptide of the invention in an amount and under conditions effective to treat or prevent, in whole or in part, the disease or disorder. The invention further provides a peptide for use in the manufacture of a medicament. For example, the peptide can be used in the manufacture of a medicament for the treatment of a blood coagulation disorder, as described in detail herein. [0092] In some embodiments, it is advantageous to administer to a subject a nucleic acid comprising a nucleic acid sequence encoding a TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention. Such a nucleic acid, in one aspect, is provided instead of, or in addition to, a TFPI-inhibitory peptide. Expression vectors, nucleic acid regulatory sequences, administration methods, and the like, are further described herein and in U.S. Patent Publication No. 20030045498. 54 [0093] A particular administration regimen for a particular subject will depend, in part, upon the TFPI- inhibitory peptide of the invention used, the amount of TFPI-binding peptide (e.g., TFPI-inhibitory peptide) administered, the route of administration, the particular ailment being treated, considerations relevant to the recipient, and the cause and extent of any side effects. The amount of peptide administered to a subject (e.g., a mammal, such as a human) and the conditions of administration (e.g., timing of administration, route of administration, dosage regimen) are sufficient to effect the desired biological response over a reasonable time frame. Dosage typically depends upon a variety of factors, including the particular TFPI-inhibitory peptide employed, the age and body weight of the subject, as well as the existence and severity of any disease or disorder in the subject. The size of the dose also will be determined by the route, timing, and frequency of administration. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect, and conventional range-finding techniques are known to those of ordinary skill in the art. Purely by way of illustration, in one aspect, the method comprises administering, e.g., from about 0.1 pg/kg to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range fi-om 1 pg/kg up to about 75 mg/kg; or 5 pg/kg up to about 50 mg/kg; or 10 pg/kg up to about 20 mg/kg. In certain embodiments, the dose comprises about 0.5 mg/kg to about 20 mg/kg (e.g., about I mg/kg, 1.5 mg/kg, 2 mg/kg, 2.3 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, 4.5 mg/kg, 5 mg/kg, 5.5 mg/kg, 6 mg/kg, 6.5 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg) of peptide. Given the chronic nature of many blood coagulation disorders, it is envisioned that a subject will receive the TFPI-inhibitory peptide over a treatment course lasting weeks, months, or years, and may require one or more doses daily or weekly. In other embodiments, the TFPI-inhibitory peptide is administered to treat an acute condition (e.g., bleeding caused by surgery or trauma, or factor inhibitor/autoimmune episodes in subjects receiving coagulation replacement therapy) for a relatively short treatment period, e.g., one to 14 days. [0094] Suitable methods of administering a physiologically-acceptable composition, such as a pharmaceutical composition comprising a peptide described herein, are well known in the art. Although more than one route can be used to administer a peptide, a particular route can provide a more immediate and more effective reaction than another route. Depending on the circumstances, a pharmaceutical composition is applied or instilled into body cavities, absorbed through the skin or mucous membranes, ingested, inhaled, and/or introduced into circulation. In one aspect, a composition comprising a TFPI-inhibitory peptide is administered intravenously, intraarteri ally, or intraperitoneally to introduce the peptide of the 55 invention into circulation. Non-intravenous administration also is appropriate, particularly with respect to low molecular weight therapeutics. In certain circumstances, it is desirable to deliver a pharmaceutical composition comprising the TFPI-inhibitory peptide orally, topically, sublingually, vaginally, rectally; through injection by intracerebral (intra parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, urethral, or enteral means; by sustained release systems; or by implantation devices. If desired, the TFPI-inhibitory peptide is administered regionally via intraarterial or intravenous administration feeding a region of interest, e.g., via the femoral artery for delivery to the leg. In one embodiment, the peptide is incorporated into a microparticle as described in, for example, U.S. Patents 5,439,686 and 5,498,421, and U.S. Patent Publications 2003/0059474, 2003/0064033, 2004/0043077, 2005/0048127, 2005/0170005, 2005/0142205, 2005/142201, 2005/0233945, 2005/0147689. 2005/0142206, 2006/0024379, 2006/0260777, 2007/0207210, 2007/0092452, 2007/0281031, and 2008/0026068. Alternatively, the composition is administered via implantation of a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device in one aspect is implanted into any suitable tissue, and delivery of the desired molecule is in various aspects via diffusion, timed-release bolus, or continuous administration. In other aspects, the TFPI- inhibitory peptide is administered directly to exposed tissue during surgical procedures or treatment of injury, or is administered via transfusion of blood procedures. Therapeutic delivery approaches are well known to the skilled artisan, some of which are further described, for example, in U.S. Patent No. 5,399,363. [0095] To facilitate administration, the TFPI-binding peptide (e.g., TFPI-inhibitory peptide) in one embodiment is formulated into a physiologically-acceptable composition comprising a carrier (i.e., vehicle, adjuvant, buffer, or diluent). The particular carrier employed is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the peptide, and by the route of administration. Physiologically-acceptable carriers are well known in the art. Illustrative pharmaceutical forms suitable for injectable use include without limitation sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U.S. Patent No. 5,466,468). Injectable formulations are further described in, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia. Pa., Banker and Chalmers. eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 56 4th ed., pages 622-630 (1986)). A pharmaceutical composition comprising a peptide provided herein is optionally placed within containers, along with packaging material that provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions include a tangible expression describing the reagent concentration, as well as, in certain embodiments, relative amounts of excipient ingredients or diluents that may be necessary to reconstitute the pharmaceutical composition. [0096] When appropriate, the TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention is administered in combination with other substances and/or other therapeutic modalities to achieve an additional or augmented biological effect. Co-treatments include, but are not limited to, plasma-derived or recombinant coagulation factors, hemophilia prophylaxis treatments, immunosuppressants, plasma factor-inhibiting antibody antagonists (i.e., anti-inhibitors), antifibrinolytics, antibiotics, hormone therapy, anti-inflammatory agents (e.g., Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or steroidal anti-inflammatory substances), procoagulants, and pain relievers. In one aspect, the method is an adjunct therapy to traditional replacement factor treatment regimens involving administration of, e.g., FXIII, FXII, FXI (e.g., IEMOLEVEN@ (Laboratoire francais du Fractionnement et des Biotechnologies, Les Ulis, France) and FXI concentrate (BioProducts Laboratory, Elstree, Hertfordshire, UK)), FX, FIX (e.g., BENEFIX* Coagulation Factor IX (Wyeth, Madison, NJ); ALPHANINE@ SD (Grifols, Los Angeles, CA); MONONINE® (CSL Behring, King of Prussia, PA); BEBULIN-VHTM (Baxter, Deerfield, IL); PROFILNINE@ SD (Grifols, Los Angeles, CA); or PROPLEX T T M (Baxter, Deerfield, IL)), FVII (e.g., ADVATETM (Baxter, Deerfield. IL); HELIXATE@ FS (CSL Behring, King of Prussia, PA); REFACTO® (Wyeth, Madison, NJ), XYNTHA TM (Wyeth, Madison, NJ), KOGENATE@ and KOGENATE@ FS (Bayer, Pittsburgh, PA); ALPHANATE@ (Grifols, Los Angeles, CA); HEMOPHIL M TM (Baxter, Deerfield, IL); KOATE@-DVI (Talecris Biotherapeutics-USA. Research Triangle Park, NC); or MONARC-M TM (Baxter, Deerfield, IL)), FVIIa (e.g., NOVOSEVEN® FVIIa (Novo Nordisk, Princeton, NJ) and FVII concentrate (Baxter Bioscience, Vienna, Austria, or BioProducts Laboratory, Elstree, Hertfordshire, UK)),. FV, FVa, FII, and/or FIII, to a subject. In some instances, the subject also receives FEIBA VH ImmunoM (Baxter BioScience, Vienna, Austria), which is a freeze-dried sterile human plasma fraction with Factor VIIU inhibitor bypassing activity, FEIBA VH ImmunoTM contains approximately equal units of Factor VIII inhibitor bypassing activity and Prothrombin Complex Factors (Factors II, VII, IX, and X and protein C). Other exemplary co-treatments include, but are not limited to, prekallikrein, high molecular weight kininogen (HMWK), Von Willebrand's factor, Tissue 57 Factor, and thrombin. Alternatively or in addition, the TFPI-inhibitory peptide is co fornulated with one or more different TFPI-inhibitory peptides. [0097] The invention thus includes administering to a subject a TFPI-binding peptide (e.g., TFPI-inhibitory peptide) of the invention (or multiple TFPI-inhibitory peptides), in combination with one or more additionally suitable substances(s), each being administered according to a regimen suitable for that medicament. Administration strategies include concurrent administration (i.e., substantially simultaneous administration) and non-concurrent administration (i.e., administration at different times, in any order, whether overlapping or not) of the TFPI-inhibitory peptide and one or more additionally suitable agents(s). It will be appreciated that different components are optionally administered in the same or in separate compositions, and by the same or different routes of administration. [0098] In some embodiments, the peptide of the invention is conjugated to a moiety, eg., a therapeutic or diagnostic moiety, such as the detection moieties and co-treatments described above. Alternatively or in addition, the peptide is administered in combination with an interaction partner (e.g., an antibody, antibody fragment, anticalin, aptamer, or spiegelmer) that (a) binds the peptide and (b) is therapeutically active and/or is linked to a moiety that provides additional functionality to the interaction partner (e.g., a therapeutic, diagnostic, or detection agent). Suitable moieties include, but are not limited to, dyes, radionuclides, radionuclide-containing complexes, enzymes, toxins, antibodies, antibody fragments, and cytotoxic agents, and, in some instances, the moiety possesses therapeutic activity (i.e., achieves an advantageous or desired biological effect). The peptide conjugates or peptide interaction partner pair is suitable for use in any of the methods described herein, such as methods of treating a subject suffering from a disease or disorder or at risk of suffering from a disease or disorder. [00991 All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. In addition, the entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. For example, where protein therapy is described, embodiments involving polynucleotide therapy (using polynucleotides/vectors that encode the protein) are specifically contemplated, and the reverse also is true. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of 58 understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The invention includes, for instance, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above. With respect to aspects of the invention described as a genus, all individual species are individually considered separate aspects of the invention. With respect to aspects of the invention described or claimed with "a" or "an," it should be understood that these terms mean "one or more" unless context unambiguously requires a more restricted meaning. With respect to elements described as one or more within a set, it should be understood that all combinations within the set are contemplated. EXAMPLES Example 1 [00100) The following example describes production, identification, and screening of peptides for binding to TFPI. [00101] Peptides candidates were obtained from commercial suppliers (e.g., PolyPeptide Laboratories SAS (Strasbourg, France) and JPT Peptide Technologies GmbH (Berlin, Germany)). Methods for synthesizing candidate peptides are provided above. Candidate peptides were synthesized as trifluoroacetate (TFA) salts with a purity >90% or >60%. All peptides were solved in DMSO to a stock concentration of 10 mM. TFPI-binding peptide sequences were identified using an mRNA display library. The mRNA display technology is superior to other library screening techniques for allowing for a diversity of 104 different sequences within a starting pool and avoiding, e.g., the in vivo steps required for phage display. In brief, the technology involves directly linking mRNA to its encoded candidate peptide through a puromycin molecule (Figure 5). The mRNA display method is further described in International Patent Publication No. WO 2005/051985 and Liu et al., Methods in Enzymology, 318, 268-293 (2000). TFPI was immobilized to a solid support via biotin and exposed to candidate peptide-RNA complexes. TFPI-bound candidate peptide-RNA complexes were isolated, and the RNA reverse transcribed to obtain coding DNA. High affinity binders were obtained following six to ten selection rounds using a competitive elusion strategy. Many of the candidate peptides were 31 amino acids in length (27 randomized amino acids and 2 amino acids flanking both ternini). 59 [00102] Selected peptides were synthesized and subjected to peptide optimization using a microarray-based scan analysis to identify peptide fragments retaining TFPI-binding affinity. For example, a micro array-based scan of JBT0047 was performed using a series of 20 amino acid fragments of the peptide, the sequences of which overlapped by 19 amino acids. N- and C-terminal truncation analysis supplemented the scan analysis. The microarray scan results demonstrated that that peptide JBT0293 bound TFPI with the highest affinity. A series of substitution mutants based on the amino acid sequence of JBT0293 was generated and tested for TFPI binding properties. [00103] The affinity of a subset of peptides for TFPI was demonstrated via an enzyme linked immunosorbent assay (ELISA)-like assay (binding (EC 50 ) ELISA) performed with biotinylated peptides. Ninety-six well MaxiSorp plates (Nunc) were coated with 3 gg/mL TFPI in coating buffer (15 mM Na 2

CO

3 , 35 mM NaHCO 3 , pH 9.6) over night. Plates were washed three times with 350 pl wash buffer (HNaT: 175 mM NaCl, 25 mM HEPES, 5 mM CaCI 2 . 0.1% Tween 80, pH 7.35), and subsequently blocked with 200 p1 2% yeast extract in HNaT for 2 hours. Plates were then washed three times with 350 pl HNaT. Biotinylated candidate peptides were diluted from a DMSO stock 1/200 in HNaT. The initial peptide concentration was 50 paM if no precipitate appeared during the 1/200 dilution of the 10 mM peptide stock solution. Pre-dilutions of the peptide stock in DMSO were conducted if precipitates formed. The diluted peptides were applied to the Maxisorp plates, serial dilutions (1/3) were generated, and the dilutions were incubated for 1.5 hours at room temperature. Incubation was followed by three wash steps (350 p HNaT). Bound peptide was detected by incubation with horseradish peroxidase-conjugated streptavidin (1 hour), followed by three wash steps with HNaT and a subsequent chromogenic conversion of added TMB (3,3'5,5'-Tetramethylbenzidin). The assay is illustrated in Figure 6A. [001041 Generally, peptide binding to immobilized TFPI was significantly above background. EC5 0 values for biotinylated peptides are given in Figures 32-39. The binding curve of one TFPI-binding peptide, JBT0132, is depicted in Figure 7. The EC 5 o of JBT0132 was calculated to be about 2.2 nM. [00105] In addition, a competition (IC 50 ) ELISA was performed using biotinylated TFPI binding peptides as "tracers" to compete for TFPI-binding with non-biotinylated candidate peptides. The assay principle is depicted in Figure 6B. Ninety-six well MaxiSorp plates (Nunc) were coated with 3 pg/mL TFPI in coating buffer (15 mM Na 2

CO

3 , 35 mM NaHCO 3 , pH 9.6) over night. Plates were washed three times with 350 p1 wash buffer (HNaT: 175 mM NaCI, 25 mM HEPES, 5 mM CaCl 2 , 0.1% Tween 80, pH 7.35), and blocked with 2 0 0p 12% 60 yeast extract in HNaT for 2 hours. Plates were then washed three times with 350 pl HNaT. Biotinylated tracer peptides were applied at a concentration corresponding to their respective

EC

9 o values determined in the binding ELISA (median if n > 2). A competitor stock solution of peptide (10 mM) was diluted 1/33.3 in HNaT without HSA, and a serial 1/3 dilution was prepared with HNaT with 3% DMSO. The dilution was further diluted with the biotinylated tracer peptide in a ratio of 1:6 (20 p 1 competitor dilution and 100 p 1 tracer peptide). The mixture of competitor and tracer peptide was applied to the TFPI-coated microtiter plate and incubated for 1.5 hours. The plates were washed three times with 350 pI HNaT. Peptide TFPI binding was detected by applying HRP-conjugated streptavidin to the microtiter plate, incubating the mixture for one hour, washing the plate three times with 350 g1 HNaT, applying TMB (3,35,5'-Tetramethylbenzidin), and detecting the subsequent chromogenic conversion of TMB by HRP. IC 50 graphs for representative non-biotinylated peptides are provided in Figures 8A-8D. ICIo measurements of peptides JBTO303, JBT0120, and JBT0224 are set forth in Table 3. TABLE 3 Peptide ICso [sM] n SD Tracer Peptide Tracer Concentration [M] JBTO303 0.119 2 0.064 JBT0131 0.0409 JBT0120 0.0189 3 0.0044 JBT0124 0.0718 JBT0224 n.a. 1 JBT0126 0.240 [00106] In addition to the competition ELISA (IC 5 o) assay, a screening assay was employed to measure higher numbers of peptides in parallel. The screening ELISA is similar to the competition IC 5 o ELISA with the exception that only three different concentrations of the competitor were employed (300 nM, 100 nM and 33.3 nM for the JBT0047 class, and 50000 nM, 16667 nM and 5556 nM for the JBT0122 class). In some instances, screening results were expressed as percent inhibition of the tracer signal in relation to a competitive peptide (competitive peptide JBT0477 for the JBT0047 family, and competitive peptide JBT1697 for the JBT0122 family). The competition IC50 assay results and the screening assay results of peptides prepared and screened in accordance with the methods set forth herein are provided in Figures 32-39. The mean IC 5 values presented in Figures 32-39 are based on a greater number of assays than the values presented in Table 3 and, therefore, the values may differ slightly. The results of the screening ELISA are presented as percent inhibition of tracer peptide JBT0131 binding. Several peptides that were analyzed using the 61

IC

50 ELISA are classified in Figures 32-39 according to their binding affinity as set forth in Table 4. TABLE4 TFPI competition ELISA IC 5 o [nM] Group <50 nM A 50 < x <100 nM B |100 - x < 250 nM C 250:5 x < 1000 nM D 1000 x < 5000 nM E 5000 x < 10000 nM F 10000 < x < 50000 nM G [00107] Exemplary TFPI-binding peptides identified using the methods described herein are presented in Table 5. Some peptides were biotinylated, and many comprise N- and C terminal lysines to promote solubility. Several peptides exhibited TFPI-inhibitory activity in model and/or plasmatic assay systems, as described below. TABLE 5 Peptide Parent Sequence SEQ 11) JBTO047 QSKKNVFVFGYFERLRAK 1 JBT0047 JBT0047 Ac-SGVGRLQVAFQSKKN4VVFGYFERLRAKLTS-NH2 253 JBT0051 JBT0047 Biotinyl-Ttds-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-NH2 962 JBT0055 JBT0047 Ac-SGVGRLQVAFQSKKNVFVFGYFERLRAKLTS-Ttds-Lys(Biotinyl)- 963 NH2 JBT0131 JBT0047 Biotiny-Ttds-AFQSKKNVFVFGYFERLRAK-NH2 964 JBT0132 JBT0047 Biotinyl-Ttds-FQSKKNVFVFGYFERLRAKL-NH2 965 JBTOI33 JBT0047 Biotiinyl-Ttds-QSKKNVFVFGYFERLRAKLT-NI2 966 JBT0155 JBT0047 Ac-KKSGVGRLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 8 JBT0158 JBT0047 Ac-KKSGVGRLQVAFQSKKNVFVFGYFERIRAKKK-NH2 9 JBT0162 JBT0047 Ac-KKGRLQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 10 JBT0163 JBT0047 Ac-KKQVAFQSKKNVFVFGYFERLRAKLTSKK-NH2 11 JBT0164 JBT0047 Ac-KKFQSKKNVFVFGYFERLRAKLTSKK-NH2 12 JBTOI66 JBT0047 Biotinyl-Ttds-KKFQSKKNVFVFGYFERLRAKLKK-NH2 968 JBT0169 JBT0047 Ac-KKAFQSKKNVFVFGYFERLRAKKK-Nfl2 254 JBT0170 JBT0047 Ac-KKFQSKKNVFVFGYFERLRAKLKK-NH2 13 JBTO371 JBT0047 Ac-KKQSKKNVFVFGYFERLRAKLTKK-NH2 255 JBT0174 JBT0047 AC-KKAFQSKKNVFVFGYFERLRAKLKK-NH2 14 JBT0175 JBT0047 Ac-KKAFQSKKNVFVFGYFERLRAKLTKK-N1H2 182 JBT0293 JBT0047 Ac-FQSKKNVFVFGYFERLRAKL-NH2 256

X

3

X

4

X

5

KX

7 N VFX X 1

GYXJ

5

X

1

RLRAKX,

2 2 JBT0294 JBT0047 Ac-YQSKKNVFVFGYFERLRAKL-NH2 257 JBT0295 JBT0047 AC-FSSKKNVFVFGYFERLRAKL-N12 713 JBT0296 JBT0047 Ac-FQNKKNVFVFGYFERLRAKL-NH2 407 JBT0297 JBT0047 Ac-FQSKNNVFVFGYFERLRAKL-N12 183 62 JBT0298 JBT0047 Ac-FQSKQNVFVFGYFERLRAKL-NH2 747 JBT0299 JBT0047 AC-FQSKKNVFAFGYFERLRAKL-NH2 408 JBT0300 JBT0047 Ac-FQSKKNVFSFGYFERLRAKL-NH2 409 JBTO301 JBT0047 Ac-FQSKKNVFTFGYFERLRAKL-NH2 470 JBT0302 JBT0047 Ac-FQSKKNVFVAGYFERLRAKL-NH2 258 JBT0303 JBT0047 Ac-FQSKKNVFVDGYFERLRAKL-NH2 184 JBT0304 JBT0047 AC-FQSKKNVFVLGYFERLRAKL-NH2 259 JBT0305 JBT0047 AC-FQSKKNVFVQGYFERLRAKL-NH2 260 JBT0306 JBT0047 Ac-FQSKKNVFVSGYFERLRAKL-NH2 185 JBT0307 JBT0047 Ac-FQSKKNVFVYGYFERLRAKL-NH2 261 JBT0308 JBT0047 AC-FQSKKNVFVFGYKERLRAKL-NH2 411 JBT0309 JBT0047 A-FQSKKNVFVFGYYERLRAKL-NH2 412 JBT0310 JBT0047 Ac-FQSKKNVFVFGYFDRLRAKL-NH2 262 JBT0311 J3BT0047 Ac-FQSKKNVFVFGYFERLRAKN-NH2 748 TFVDERLLYFLTIGNMGMYAAQLKF 3 JBT0049 JBT0049 Ac-SGNTFVDERLLYFLTIONMGMYAAQLKFRTS-NH2 3025 JBT0053 JBT0049 Biotinyl-Ttds-SGNTFVDERLLYFLTIGNMGMYAAQLKF{RTS-NH2 3006 JBT0057 JBT0049 Ac-SGNTFVDERLLYFLTIGNMGMYAAQLKFRTS-Ttds-Lysin(biotin)- 3018 NH2 JBT0190 JBT0049 Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKIRTSKK-NH2 3031 JBT0193 JBT0049 Ac-KKSGNTFVDERLLYFLTIGNMGMYAAQLKFKK-NH2 3073 JBT0197 JBT0049 Ac-KKTFVDERLLYFLTIGNMGMYAAQLKFRTSKK-NH2 3076 VIVFTFRHNKLIGYERRY 4 JBT0050 JBT0050 Ac-SGRGCTKVIVFTFRHNKLIGYERRYNCTS-NH2 3047 JBT0054 JBT0050 Biotiny-Ttds-SGRGCTKVIVFTFRHNKLIGYERRYNCTS-NH2 3002 JBT0058 JBTOO50 Ac-SGRGCTKVIVFTFRHNPKLIGYERRYNCTS-Ttds-LysiI(biotin)-NH2 3003 JBT0129 JBTOOSO Ac-SGRGCTKVVFTFRHNKLIGYERRYNCJTS-NH2 3026 JBT0130 JBTOO-50 Biotinyl-Ttds-SGRGICTKVIVFTFRHNKLIGYUsRRYNCI'S-NH2 3001 JBT0205 JBT0050 Ac-KKSGRGCTKVIViFTFRHNKLIGYERRYNCTSKK-NH2 3029 JBT0208 JB''0050 Ac-KKSGRGCTKVIVFiFRIHNKLIGYERRYNKK -NI2 3027 JBT0211 JBT0050 Ac-KKGCTKVIVFi'FIiINKLIGYERRYNCTSKK-NI12 3032 JBT0212 JBT0050 Ac-KKKVIVFFI-'I INKLIGYERRYNC'SKK-NI12 3033 JB'0217 JBT0050 Ac-KKTKVIVFIFRI INKLIGYERRYKK-NI12 3062 JBT0218 JBTOO50 AC-KKKVIVFTFRINKTGYFRRYNKK-N12 3063 JBT0219 JBT0050 Ac-KKVIVFTFRIINKLIGYERRYNCKK-NH12 3030 GVWQTIPRYFWTMWPDIKGEVIVLFGT 5 JBTO1O1 JBT0101 Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVJFGTSKK-NH2 3036 JBT0052 JBTO101 Biotinyl-Ttds-KKSGVWQTHPRYFWTMWPDIKGEVIVTFGTSKK-NH2 3004 JBT0103 JBT0101 Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLJFGTS-Ttds-KK- 3005 Lvsin(biotinyl)-NH2 JBT0178 JBTO101 Ac-KKSGVWQTHPRYFWTMWPDIKGEVIVLFGTKK-NH2 3028 JBT0182 JBT0101 AC-KKGVWQTHPRYFWTMWPDIKGEVIVLFGTSKK-NH2 3037 KWFCGMRDMKGTMSCVWVKF 6 JBT0120 JBT0120 Ac-SGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTS-NI2 1047 JBTO]24 | Biotinyl-Ttds-SGASRYKWF[CGMRDMKGTMSCJVWVKFRYDTS-NH2 1290 JBT0247 JBT0120 Ac-SGASRYKWFCGMRDMKGTMSCVWVKFRYDTS-NI2 1213 J1BT0248 JBT0120 Ac-KKSGASRYKWF[CGMRDMKGTMSC]VWVKFRYDTSKK-NH2 1001 JBT0251 JBT0120 AC-KKKWFCGMRDMKGTMSCVWVKFKK-NH2 1202 JBT0252 JBT0120 AC-KKCGMRDMKGTMSCVWVKFRYDKK-NH2 1215 ASFPLAVQLHVSKRSKEMA 7 JBT0122 JBT0122 Ac-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NH2 2002 JBT0126 JBT0122 Biotinyl-Ttds-SGYASFPLAVQLHVSKRSKEMALARLYYKTS-NI2 2498 JBT0221 JBT0122 Ac-KKSGYASFPLAVQLHVSKRSKEMALARLYYKTSKK-NH2 2003 JBT0224 JBT0122 AC-KKSGYASFPLAVQLIVSKRSKEMALARLYYKK-NH2 2298 JBT0225 JBT0122 Ac-KKSGYASFPLAVQLHVSKRSKEMALARKK-NI2 2128 JBT0226 JBT0122 AC-KKSGYASFPLAVQLIIVSKRSKEMAKK-NH2 2299 JBT0228 JBT0122 Ac-KKASFPLAVQLHVSKRSKEMALARLYYKTSKK-NH2 2016 JBT0232 JBT0122 AC-KKGYASFPLAVQLHVSKRSKEMKK-NH2 2303 JBT0233 JBT0122 Ac-KKYASFPLAVQLIIVSKRSKEMAKK-NI2 2304 63 [00108] This example provides exemplary methods of generating and characterizing TFPI inhibitory peptides. All peptides in Table 5 were found to bind human TFPI-Ict. Mutation analysis demonstrated that at least one amino acid in a TFPI-binding peptide may be substituted while retaining affinity for TFPI. The peptides of Table 5 tested in ELISA assays bound TFPI-la with an ECso of less than 10 pM (1 x 10-5 M) and an IC 50 of less than 50 pM. Example 2 [00109] Selected TFPI-binding peptides were further characterized in terms of "anti target" binding. This example demonstrates that TFPI-inhibitory peptides exhibit reduced affinity for non-TFPI-1 proteins. [00110] TFPI-2 was selected as an anti-target because of its similarity to TFPI- 1. The binding kinetics of TFPI-binding peptides to human TFPI- I (residues 29-282 fused at the C terminus to a 10 His-tag; MW 41 kDa (R&D Systems, Minneapolis, MN; catalog number 2974-PI)) murine TFPI-l (residues 29-289 fused at the C-terminus to a 10 His-tag; MW 41kDa (R&D Systems; catalogue number 2975-PI)), and TFPI-2 (R&D Systems, Minneapolis, MN) were studied using a BlAcore 3000TM surface plasmon resonance assay (GE Healthcare, Chalfont St. Giles, UK). TFPI proteins were immobilized on a C1 chip (GE Healthcare, Order Code: BR-1005-40) by amine coupling chemistry aiming for 500 RU. Several TFPI-binding peptides were employed as analytes for interacting with the immobilized TFPI proteins. A flow rate of 30 pl/min was utilized. After 180 seconds, 180 Pl of peptide solution was injected at six different concentrations ranging fiom 3.84 nM to 656.25 nM, followed by a dissociation time of 480 seconds. The chip was regenerated with 45 p 10 mM NaOH. Each binding experiment was preceded and followed by four measurements with HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% P20) plus 1% DMSO and 0.8% P80. BlAevaluation@ Version 4.1 software (GE Healthcare) was employed to analyze the data. Sensorgrams were fitted to a 1:1 Langmuir binding curve to determine km, and kff and calculate K[). [00111] Certain tested peptides, e.g.. JBT0050, JBT0121, JBT0205 and JBT0211, bound to the blank cell and binding constants from those sensorgrams could not be determined. JBT01 33 showed weak binding to TFPI- 1. Sensorgrams from other peptides gave reliable binding constants. Results from BlAcore analysis of several TFPI-inhibitory peptides is 64 provided in Table 6 and Figures 19-21. Each of the peptides listed in Table 6 presented a Kn of less than 10 [M. Sensorgrams of two of the peptides are provided as Figures 9A and 9B. TABLE 6 Peptide k.. (1/Ms) kff (1/s) K 0 (M) JBT0047 4.0 x 10 1.9 x 10-2 4.7 x 10-" JBT0120 1.17 x 106 4.78 x 102 4.08 x 10 ~ JBT0131 1.4 x 10 6.0 x 10 - 4.31 x 10-' JBT0132 3.55 x 10 4 3.26 x 10-2 9.17 x 10-' JBT0224 6.39x i0 1.95 x 10 2 3.05 x 10-' JBT0293 6.0 x 10 5 5.6 x 10-2 9.5 x 10 JBT0297 5.0 x 107 1.4 x 10- 2 2.9 x 10 JBT0303 8.13 x 10F 2.75 x 102 3.4 x 10 JBT0305 7.5 x 10 3.1 x 10- 6.1 x 1 [00112] Interaction with the TFPI-2 anti-target also was examined. The maximum signal generated from candidate peptide interaction with human TFPI-2 was much lower than the signals obtained with TFPI-1 as an interaction partner. Kinetic analysis of the low TFPI-2 binding signals was prone to error; therefore, visual comparison of sensorgrams was used to estimate binding affinity. A sensorgram illustrating JBT0120 binding to TFPI-1 and TFPI-2 is provided as Figures IOA and 10B. JBT0120 binds TFPI-2 with 10-fold lower affinity compared to its binding affinity for TFPI-1. JBTO132 also was found to exhibit at least 10 fold greater affinity for TFPL- I than TFPI-2. [00113] The data provided by this example confirm that TFPI-inhibitory peptides specifically bind TFPI- 1. Example 3 [00114] The following example describes the characterization of TFPI-inhibitory activity of select peptides identified in Example 1 using a FXa inhibition and extrinsic tenase inhibition assay. Both assays are predictive of activity in plasmatic systems. The extrinsic tenase assay gives insight into the influence of the peptides on (a) the interaction of FXa and TFPI and (b) the interaction of the FXa-TFP1 complex with the TF-FVlIa complex. The FXa inhibition assay measures a peptide's influence on the interaction of FXa and TFPI only. [00115] The extrinsic tenase complex is responsible for FX and FIX activation upon initiation of the coagulation process. The extrinsic complex is composed of FVIa, Tissue Factor (TF), and FX substrate. To determine the influence of peptides on the TFPI-mediated 65 inhibition of the extrinsic tenase complex, a coupled enzyme assay was established. Peptides were diluted 1/6.25 from 10 mM stocks (in DMSO) and further diluted by serial 1/4 dilutions in DMSO to prevent unwanted precipitation. TFPI was diluted in HNaCa-HSA (25mM HEPES; 175mM NaCl; 5mM CaCl2; 0,1% HSA; pH 7.35). FVIa, lipidated TF, phospholipid vesicles (DOPC/ POPS 80/20), and chromogenic substrate specific for FXa (S 2222 (available from DiaPharma, West Chester, OH)), all diluted in HNaCa-HSA, were added to 96-well plates. After an incubation period, TFPI and peptide dilutions were added, resulting in a final concentration of 2.5% DMSO. FX activation was initiated by adding FX to the wells. FXa-mediated chromogenic substrate conversion was determined by observing an increase in absorbance using a micro-plate reader. The amount of FXa generated at certain time points was calculated from the OD readings. FXa generated at 20 minutes after start of the reaction was considered for calculation of EC 5 0 from plots of peptide concentration versus the inhibition of TFPI (%). [00116] The functional inhibition of TFPI also was examined using a FXa inhibition assay. A FXa-specific chromogenic substrate (S-2222) and TFPI, both diluted in HNaCa-HSA, were added to 96 well plates. Peptides were diluted 1/6.25 from 10 mM stocks (in DMSO) and further diluted by serial 1/4 dilutions in DMSO to prevent unwanted precipitation. The peptide dilutions (2.5 il) were added to the 96 well plates, resulting in a final concentration of 2.5% DMSO. The conversion of chromogenic substrate was triggered by the addition of FXa, and the kinetics of the conversion were measured in a micro-plate reader. Because TFPI inhibits FXa slowly, OD readings after 115 minutes were considered for calculation of the EC5 0 from plots of peptide concentration versus the inhibition of TFPI (%). [00117] Results from the extrinsic tenase assay and FXa inhibition assay are provided in Table 7 and Figures 22-27. TABLE 7 FXa Inhibition Assay Extrinsic Tenase Assay EC50 [pM] % inhibition @ 2.5 ECso [pM] % inhibition @ 2.5 pM pM JBT0120 0.9 45 0.9 45 JBT0132 1.2 36 0.1 10 JBT0224 n.a. 26 3.5 18 JBT0303 1.2 61 n.a. 8 [00118] Referring to Table 7, JBTO 120, JBT0132, and JBT0224 restored extrinsic complex-mediated FX activation in the presence of TFPI-l with an EC 5 0 of < 2 pM, resulting in between about 20% to about 60% inhibition of TFPI activity. JBT0047 (EC 50 =1.4 pM), 66 JBT0131 (EC 0 =2.2 pM), and JBT0293 (EC 5 o=2.9 pM) also restored extrinsic complex activity in the presence of TFPI-i. In addition, JBT0120, JBT0132, JBT0224, and JBT0303 restored FXa activity in the presence of TFPI-1 with an ECso of < 5 pM, resulting in between about 5% to about 50% inhibition of TFPI activity, in the FXa inhibition assay. JBT0047

(EC

50 =0.7 pM), JBT0131 (EC 50 =8.2 pM), JBT0293 (EC 50 =1.3 pM), JBT0297 (EC 5 o=0.6 pM), and JBT0305 (EC 50 =2.3 pM) also restored activity of FXa in the presence of TFPI- I in the FXa inhibition assay. This example confirms that peptides of the invention are TFPI antagonists. Example 4 [00119] In this example, the TFPI inhibitory activity of peptides is established using a plasma-based assay. [00120] The influence of peptides on thrombin generation was measured in duplicate via calibrated automated thrombography in a Fluoroskan Ascent® reader (Thermo Labsystems, Helsinki, Finland; filters 390 nm excitation and 460 nm emission) following the slow cleavage of the thrombin-specific fluorogenic substrate Z-Gly-Gly-Arg-AMC (Hemtker, Pathopkysiol. Haemost. Thromb., 33, 4-15 (2003)). Plasma from patients with FVII or FIX deficiency (George King Bio-Medical Inc., Overland Park, KN) was obtained for testing. The residual coagulation factor activity for each of the plasmas was lower than 1%. As a model for antibody-mediated FVIII deficiency, frozen pooled normal plasma (George King Bio-Medical Inc., Overland Park, KN) was incubated with high titer, heat inactivated, anti human FVIII plasma raised in goat (4490 BU/ml; Baxter BioScience, Vienna, Austria) giving rise to 50 BU/mL. The plasmas were mixed with corn trypsin inhibitor (CTI) (Hematologic Technologies, Inc., Essex Junction, VT) to inhibit Factor XIIa contamination, resulting in a final concentration of 40 pg/mL. [00121] Pre-warmed (37 0 C) plasma (80 gL) was added to each well of a 96 well micro plate (Immulon 2HB, clear U-bottom; Thermo Electron, Waltham, MA). To trigger thrombin generation by Tissue Factor, 10 pL of PPP low reagent containing low amounts (12 pM) of recombinant human Tissue Factor and phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine (48 pM.) (Thrombinoscope BV, Maastricht, The Netherlands) were added. Peptides were diluted 1/7.5 from 10 mM stocks with DMSO, and further diluted 1/8.33 with Aqua-Dest resulting in a DMSO concentration of 12%, providing a 0.5% DMSO concentration in the final assay mix. 67 Just prior putting the plate into the pre-warmed (37 0 C) reader, 5 tL of HEPES buffered saline with 5 mg/mL human serum albumin (Sigma-Aldrich Corporation, St. Louis, Missouri, USA) or 12% DMSO in Aqua-Dest was added, followed by addition of the peptide dilutions or reference proteins (FVIII Immunate reference standard (Baxter BioScience, Vienna, Austria); Factor ViI Inhibitor By-Passing Activity (FEIBA) reference standard (Baxter BioScience, Vienna, Austria); NovoSeven (Novo Nordisk, Denmark); and purified human plasma FIX (Enzyme Research Laboratories, South Bend, IL)). Thrombin generation was initiated by dispensing into each well 20 p L of FluCa reagent (Thrombinoscope BV, Maastricht, The Netherlands) containing a fluorogenic substrate and HEPES-buffered CaC 2 (100 mM). Fluorescence intensity was recorded at 37 0 C. [00122] The parameters of the resulting thrombin generation curves were calculated using ThrombinoscopeTM software (Thrombinoscope BV, Maastricht, The Netherlands) and thrombin calibrator to correct for inner filter and substrate consumption effects (Hemker, Pathophysiol. Haenwst. Thromb., 33, 4-15 (2003)). For calculating the thrombin generating activity of certain peptide concentrations equivalent to the reference proteins (e.g., FVIII Immunate@ reference standard, FEIBA reference standard), the thrombin amounts at the peak of each thrombin generation curve (peak thrombin, nM) were plotted against the standard concentrations, and fitted by a non-linear algorithm. Based on this calibration, FVIII Immunate, FIX, FEIBA or NovoSeven equivalent activities were calculated. Results for various peptides are provided in Figures 12-18 and 28-30. Representative results are provided in Table 8. (* denotes that FVII deficient plasma was obtained from a different donor.) TABLE8 % FVIII-equivalent activity FEIBA-equivalent activity in in FVIII deficient plasma @ FVII inhibited plasma @ 10 pM 10 pM peptide peptide [mU/ml] JBT0120 37.4* 298 JBT0132 5.3 41 JBT0224 16.2 191 JBT0303 20.8 253 [00123] With reference to Table 8, JBT0120, JBT0132, JBT0224, and JBT0303 improved TFPI-dependent thrombin generation in FVII-depleted plasma to levels exceeding I % of the level of thrombin generation in plasma containing FV1II (% FVIII-equivalent activity). The tested peptides exhibited approximately 5%-40% FVIII-equivalent activity in FVJI-deficient 68 plasma. JBT0120 and JBT0132 improved peak thrombin and peak time, dose dependently, as illustrated in Figures 1 IA and 11B. Example 5 [00124] The following example demonstrates that the peptides of the invention can be modified by the addition of moieties that enhance physicochemical or pharmacokinetic properties of the peptides. As illustrated below, the addition of 40 kDa PEG to peptides described herein dramatically improved the pharmacokinetic behavior of the peptides. [00125] Methods of conjugating chemical or biological moieties to peptides are known in the art. To add PEG (polyethylene glycol) to the peptides describe herein, a functional group (AOA = aminooxy acetate) was added to the N-terminus of the peptides for coupling to aldehydes and ketones. Alternatively, a cysteine was added to the C-terminal part of the peptide for coupling with maleimid (Hermanson, Bioconjugate Techniques, Academic Press (1996)). The peptides (JBTI586) AOA-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 166) and (JBT1587) Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167) were used for N-terminal and C-terminal modification with PEG, respectively. AOA FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 166) and Ac FQSKGNVFVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167) were incubated with excess 40 kDa mPEG-Propionaldehyde (SUNBRIGHT ME-400AL2, NOF, Japan) and 40 kDa mPEG-maleimide (SUNBRIGHT ME-400MA, NOF, Japan), respectively. The resulting PEGylated peptides, JBT1 853 and JBT1855, show similar affinities compared to the starting structure Ac-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (JBT0740) (SEQ ID NO: 66). [00126] The resulting PEGylated peptides demonstrated significantly increased plasma stability and prolonged plasma half-life in mice. Figure 31 illustrates the results from a pharmacokinetic analysis of the free peptide JBT0740 (Ac-FQSKGNVFVDGYFERL-Aib AKL-NH2) (SEQ ID NO: 66) compared to the C-terminally PEGylated peptide JBT1 855 (Ac-FQSKGNVFVDGYFERL-Aib-AKLC(PEG(40kD))-NH2) (SEQ ID NO: 252). In contrast to the unPEGylated peptide, the PEGylated peptide is present at high concentrations in mouse plasma at 100 minutes post-administration. The unPEGylated peptide is rapidly cleared from the plasma. 69

Claims (119)

1. A peptide that binds TFPJ, comprising the following structure of formula (I): X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012 X1013-X1014-X101-X1016-X1017-X1018-X1019-X1020 (I) (SEQ ID NO: 3116): wherein X1001 is an amino acid selected from the group consisting of Bhf, C. D, F, G, H, 1 K, L, M, N, Nmf, Q, R, T, V, W and Y; wherein X1002 is an amino acid selected from the group consisting of G, K and Q; wherein X1003 is an amino acid selected from the group consisting of A. Aib, Bhs, C, D, E, F, 0, H, 1L K, L, M, N, P, Q, R, S. T, V,W and Y; wherein X 1004 is an amino acid selected from the group consisting of A, Aib, Bhk, C, D, E, F, G H, I, K k, L, M, Nmd, P, Q, R, S, T, V, W and Y; wherein X1005 is an amino acid selected from the group consisting of a. A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M N, Nmg, p, Q, R, S, T, V, W and Y; wherein X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, G , I, K, L, M, N, Q, R, S T, V, W and Y; wherein X1007 is an amino acid selected from the group consisting of A, F, G, 1, K, L, Nmv, P, Q, S, V, W and Y; wherein X1008 is an amino acid selected from the group consisting of F, H, K, W and Y; wherein X1009 is an amino acid selected from the group consisting of A, Aib, f. I, K, S, T and V; wherein X110 isa an amino acid selected from the group consisting of A, Aib. C. 7, E F, G, H, 1, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y; 70 wherein X1O11 is anmino acid selected from the group consisting of Aib, C, K, G and Nmg; wherein X1012 is Y; wherein X1013 is an amino acid selected from the group consisting of A. Aib, C, E, F, G, H, K, L, MQ, R, W and Y; wherein X1014 is an amino acid selected from the group consisting of A, Aib, Bhe C, D, E, F, G, H, I, K, LI M, N, P, Q, R, S, T. V, W and Y; wherein X1015 is an anino acid selected from the group consisting of (omega-methyl)-R, D, E, K and R; wherein X1016 is L; wherein X 017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr. C, Cm, Cit, D, Dab, Dap, E, Eag, Eew, F, G. H, I-Har, Hci, H1e, 1, K, L, M M N. Nie, Nva, Opa, Orn, Q, R, S, T, V, W and Y; wherein X1018 is an amino acid selected from the group consisting of A. Bal. C, D, E, F, G, H, I, K, L, M, N. Q, R, S, T, V. W and Y; wherein X1019 is an amino acid selected from the group consisting of Bhk, K, R and V; and wherein X1020 is either present or absent, whereby in case X1020 is present it is an amino acid selected from the group consisting of Aib, Bhl, C, F, G, IH, I, K, L, Nml Q, R, S, T, V, W and Y.

2. The peptide according to claim I wherein XIO1 is an amino acid selected from the group consisting of CF, IK, L, Nmf. V M,.Wand Y; 71 wherein X1002 is Q; wherein X1003 is an amino acid selected from the group conaskting of A, C. D, E. H, K, M, 1, NpQ R, S, T and V; wherein X1004 is an amino acid selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y; wherein XlOO5 is an amino acid selected from the group consisting of a, A. Aib, Bal, C, d, E, D, F, G1, K, k, L, M, N, Nmg, p. Q, R, 8, T and Y; wherein X1006 is an amino acid selected from the group consisting of A, Btq, C, D. G, 1, K, H, L, M, N, Q, R, S, V and Y; wherein X1007 is an amino acid selected from the group consisting of 1, K, L, Q, V and Y; wherein XIOOS is an amino acid selected from the group consisting of F, H and Y; wherein X1009 is an amino acid selected from the group consisting of f, I and V; wherein X1010 is an amino acid selected from the group consisting of A. D, E, F., G, H, K, L, M, N, P, Q, R, S, T, V, W and Y; wherein Xl 011 is an amino acid selected from the group consisting of G and Nmg; wherein X1012 is Y; wherein X1013 is an amino acid selected from the group consisting of Aib, C, F, H, L, W and Y; wherein X1014 is an amino acid selected f-m the group consisting of A. Aib. Bhe, C, D, E, H, 1, K, L, M, N, Q, R, S, T, V, W and Y; wherein X1015 is an amino acid selected from the group consisting of E and R; 72 wherein X1016 is L; wherein X 1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, K, L, M, N, Nle, Nva, Opa, Om, R, S, T, V and Y; wherein X1018 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L. M, N, Q, R, V and W; wherein X1019 is an am acid selected from the group consisting of K and R; and X1020 is either present or absent, whereby in case X1020 is present it is an amino acid selected from the group consisting of Aib, Bhl. F, K, L, R and W. 3, The peptide according to any of claims I to 2, wherein X1001 is an aino acid selected from the group consisting of F, L, Y and M; wherein X1002 is Q; wherein X1003 is an an mino acid selected from the group consisting of M, Q, R, S, T and C; wherein X1004 is an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, 1, Y, M and W; wherein X 1005 is an amino acid selected from the group consisting of a. Aib, D, d, G, H, K, k, N. Nng, p, Q, R, A. E, C and M; wherein X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q: R S and M; wherein X1007 is an amino acid selected from the group consisting of I and V; wherein X1008 is an amino acid selected from the group consisting of F. H and Y; 73 wherein X1009 is V; wherein X101O is an amino acid selected from the group consisting of A, D, E, K, M N, Q, R F, H, P, S, W and wherein X1O11 is G; wherein X1012 is Y; wherein X1O13 is an amino acid selected from the group consisting of C and F; wherein X1014 is an amino acid selected from the group consisting of A, C, D, E, K. L, I, N, Q, R, T, V and Aib; wherein X1015 is R; wherein X1016 is L; wherein X1017 is an amino acid selected from the group consisting of A. Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hie, K, Ne, Nva, Opa, Orn, R, 1, L, S and M; wherein X1018 is an amino acid selected from the group consisting of A, L, N, I and R; wherein X1019 is K; and wherein X1020 is an amino acid selected from the group consisting of K and L.

4. The peptide according to any one of claims I to 3, comprising the following structure of formula (II): X1000X101 X10P04-X1005-X

006-X1007-X 0- I X1012%X1013-X1014-X1015-X10|16-X1017-Xl118-X1019 (1) (SEQ ID NO: 3122) 74 wherein X1000 is an amino acid which is selected from the group consisting of A, E and P and wherein any one of X1001 to X1019 is as defined in any one of claims I to 3, preferably claim 2 and more preferably clahn 3. 5. The peptide according to claim 4, wherein the peptide consists of the structure of formula (11). 6. The peptide according to any one of claims 1 to 5, wherein the IC 50 of the peptide is less than 1000 nM.

7. The peptide according to any one of claims 2 to 5, wherein the IC 5 of the peptide is less than 250 nM.

8. The peptide according to any one of claims 3 to 5, wherein the IC, (of the peptide is less than 50 nMi

9. The peptide according to any one of claims 6 to 8, wherein the IC 50 is determined by competition enzyme-linked imrnmunosorbent assay (ELISA).

10. A peptide that binds TFPL, comprising the following structure of formula (Il): XI001-Q-X1003-XI004-X1005-XI006-IV-X1008-V-X1010-G-Y-C/F-XI014-R-L-X1017 X1018-K-K/L (III) (SEQ ID NO: 3117) wherein X1001, X1003, X10(4, X1005, X 006, X1008, X1010, X1014, X1017 and X1018 are each independently selected from any amino acid.

11. The peptide according to claim 10. wherein 1Cro of the peptide is less than 1000 nM as determined by competition ELISA.

12. The peptide according to any one of claims 10 to 11, wherein X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L,i. N, Nmf, Q, R, T, VW and Y; 75 preferably X1001 is an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M. W and Y; and more preferably X1001 is an amino acid selected from the group consisting of F, L, Y and M.

13. The peptide according to any one of claims 10 to 12, wherein XI 003 is an amino acid selected from the group consisting of A, Aib, Bhs/ C, D, E;,F, (3, H, I, K, L, M, N, P, Q, R, S, T, V,W and Y; preferably X1 003 is an amino acid selected from the group consist ting of A, C, D, E. H, K, M IN, Q, R, ST and V; and more preferably X1003 is an amino acid selected from the group consisting of M, Q, R, S. T and C.

14. The peptide according to any one of claims 10 to 13, wherein X1004 is an amino acid selected from the group consisting of, A, Aib, Bhk, C, D, 13, F, G, H, I. K, k, L. M, N, Nmk, P, Q, R, S, T, V, W and YA preferably X1 004 is an amino acid selected from the group consisting of A, Aib, C, D, E3, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, W and Y; and more preferably X1f004 is an amino acid selected from the group consisting of Aib, K, L, P. R, E, G,1I, Y, M and WV.

15. The peptide according to any one of claims 10 to 14, wherein Xl1005 is an amino acid selected from the group consisting of a, A, Aib, Bal; C, 1D, d,. F, V. , H, K, k, L, M, N, Nmg, p, Q. R, 8, T, V, W and Y; preferably XIOO5 is an amino acid selected from the group consisting of a, A, Aib, Bat C, d, E, D, F, C, Hi, K, kc, L, M, N, Nmg, p, Q. R, S, T and Y; and more preferably X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, 1, K, k, N, Nmg, p, Q, R, A, E, C and M.

16. The peptide according to any one of claims 10 to 15, wherein X1006 is an amino acid selected from the group consisting of A, Aib ltq, C, D, E, F, G, H, 1, K, L, M, N, Q, R, S, T, V, W and Y; preferably X1006 is an amino acid selected from the group consisting of A, Btq, C, D, ,1 K, H, L, M, N, QR, R , V and Y; and more preferably X1006 is an amino acid selected from the group consisting of A, C, D, 0, Hl, K, N, Q, R, S and M,

17. The peptide according to any one of claims 10 to 16, wherein XIOOS is an amino acid selected from the group consisting of F, H, K, W and Y; and preferably XIOOS is an amino acid selected from the group consisting of F, H and Y,

18. The peptide according to any one of claims 10 to 17, wherein X|010 islan amina acid selected from the group consisting of A, Aib. C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, W and Y; preferably XIOIO is an amino acid selected from the group consisting of A, D, E, F, H, K, L, M, N P, Q., R, S. T, V, W and Y; and rnore preferably X1010 is an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H. P, > V. W and Y. 1.9. The peptide according to any one of claims 10 to 18, wherein X1014 is an amino acid selected from the group consisting of A, Aib, Bhc, C, D, E, F, G, J, 1, K. L, NI, N, P, Q, R, S, T, V, W and Y 77 preferably X1014 is an amino acid selected frorn the group consisting of A, Aib, Bhe, C, D, E T, L K, L. M, N, Q, R, S, T, V, W and Y; and more preferably X1014 is an amino acid selected from the group consisting of A, C, D., EK, L, M, N, Q, R, T, V and Aib.

20. The peptide according to any ore of claims 10 to 19, wherein X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A. Aib, Bhr, C, Cha, Cit, D. Dab. Dap, , Eag, ew, F, G, H Har, Hci, Hile, 1, K, L, M, N, NIe, Nva. Opa, Orn. Q, R. S, T, V. W and Y; preferably X1017 is an amino acid selected from the group consisting of (omega-methyl)-R, A, Aib, Bhr, C, Cha, Cit. Dab, Dap, Eag, Eew, F, H ar, i, Hie 1, K, L, M, N, Nie, Nva, Opa, Orn, R, S, T, V and Y; and more preferably X1017is an amino acid selected from the group consisting of A, Aib, C, Cha, Dab, Dap, fEag, Eew, lar, Hi, Hle, K, Nie, Nva, Opa, On, R, 1, L, S and M.

21. The peptide according to any one of claims 10 to 20, wherein X1018 is an amino acid selected from the group consisting of A, Bal. C, D, E, F, G, H, L K, L, M, N, Q, R, S, T, V, W and Y; preferably X101S is an amino acid selected from the group consisting of A, C, D, B, F, 1, K, L, M. N, Q, R, V and W; and more preferably X1018 is an amino acid selected from the group consisting of A, L, N, M and R.

22. The peptide according to anyone of claims I to 21 further comprising one or more N terminal amino acids) directly linked to XiO1, wherein the N-terminal amino acids) comprise the amino acid sequence selected from the group consisting of '78 X1 000, X999-X1000, X998-X999-X 1000. X997-X998-X999,X000 (SEQ ID NO: 3123) X96-X997-X998-X999-X1000 (SEQ ID NO: 3124), X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125), X994-X995-X996-X997-X998-X999-XI000 (SEQ ID NO: 3126), X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127), X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3128), X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3129), and X990-X99 1 -X992-X993-X994-X995-X996-X997-X998-X999-X 1000 (SEQ JD NO: 3130), wherein X1000 is A or K, X999 is V or K, X998 is Q or K, X997 is L or K, X996 is R or K, X995 is G or K, X994 is V or K, X993 is G or K, X992 is S or K, X991 is K, and X990 sK,

23. The peptide according to anyone of claims 1 to 22 further comprising one or more C terminal amino acids) directly linked to X1020, wherein the C-terminal amino acids) comprise the amino acid sequence selected from the group consisting of X102I X102 X1022, X1021-X1022-X1023, and X1021 -X1022-X1023-X1024 (SEQ ID NO: 3131), wherein X1021 is T or K, X1022 is S or K, X1023 is K, and X1024 is K.

24. The peptide according to any one of clams I to 23, wherein the peptide contains at least two cysteine residues, preferably the peptide contains two cysteine residues, wherein the at least two cysteine residues are spaced apart by at least three amino acid -esidues of any of formulae (I) to (i) and wherein the at least two cysteine residues form together an intramolecular disulfide bond.

25. The peptide according to claim 24, wherein the at least two cysteine residues are spaced apart by more than three amino acid residues, 79

26. The peptide according to any one of claims 24 to 25, wherein any two of X1000, X1001, X1003, X1004, X1005, X1006, X1O1O 10, X X11, . 3 X1014, X1017, X1018, X1020 and X1021 is C.

27. The peptide according to any one of claims 24 to 26, wherein the peptide contains two cysteine residues, wherein one of X1000, X1005, X1010 and X1014 is C; and wherein one of X1006, X1010, X1017 and X1021 is C.

28. The peptide according to claim 27, wherein X1000 and X1006 are C; or X1000 and X1010 are C; or X1000 and X1017 are C; or X1005 and X1017 are C; or X1010 and X1017 are C; or X1010andXIO21 are C; or X1014 and X1021 are C.

29. A peptide that binds TFPi compri sing an amino acid sequence of at least 60% identity to the sequence of formula IV: Ac-FQSK-NmgNVFVDGYFERL-Alb-AKL-NH2 (IV) (SEQ ID NO: 164)

30. The peptide according to claim 29, wherein the amino acid sequence identity is 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95 % or 100%. 80

31. The peptide according to any one of claim 29 to 30, wherein the peptide comprises an amino acid sequence as defined in any of claims I to 21.

32. A peptide consisting of the amino acid sequence selected from the group consisting of SEQID NOs: 8-741, 744-968, and 971-978.

33. A peptide that binds TFPI, comprising the following structure of formula V: X200I -X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X20 I0-X201 I-X20 12 X203X204-X2015-X201 6-X20 17-X20 18]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118) wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L. P, R. S. T, V and W; wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G; H, 1, K, L, M, P, R, S, T, V and W; wherein X2003 is an amino acid selected from the group consisting of A, F, , K, L, R, S, T, V, W and Y; wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, S, T, V and W; wherein X2005 is W; wherein X2006 is an amino acid selected fron the group consisting of F H. 1, K, L R, V and W; wherein X2007 is an amino acid selected from the group consisting of C, Ucy, Dap and K, preferably selected from the group consisting of C and Hey; wherein X2008 is an amino acid selected from the group consisting of A, R, S and T; 81 wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Ne p R, Sem and V; wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V; wherein X201 I is an amino acid selected from the group consisting of D, E, G, S, and. T; wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e. F, f, G, I, K, k, L. 1, M, m, Nle, nie, P, p, R, r, S, s, Sen, T, t, V, v , W and w; wherein X2013 is an amino acid selected from the group consisting of A, D. d, E, e, F, G, 1, K, L, R, S, s, T. V and W; wherein X2014 is an amino acid selected from the group consisting of A, D, E F, F 1, 1. L. M, R, S, T, V and W; wherein X2015 is an amino acid selected from the group consisting of A, D , F, ,1, K L, M, NIe, R, S, T, VandW; wherein X2016 is an amino acid selected from the group consisting of A. D, E, F, I K. L, M, Nie, R, S, Sem, T, V, W and Y; wherein X2017 is an amino acid selected from the group consisting of A, D, E, F, G. 1, K, L. R. S. T, V, W and Y; wherein X2018 is an amino acid selected from the group consistng of C and D, preferably C; wherein X2019 is an amino acid selected from the group consisting of A, F, 1, L, S, T, V and W; wherein X2020 is an amino acid selected from the group consisting of F and WV wherein X2021 is an amino acid selected from the group consisting of I, L and V; 82 wherein X2022 is an amino acid selected from the group consisting of A.D, E, F G, I, K, L, P R, S, TVandW; wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, S, T, V, W and Y; wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.

34. The peptide according to claim 33, wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S; wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, M, P, R and S; wherein X2003 is an amino acid selected from the group consisting of A, F, K, S and Y whereli X2004 is an amino acid selected from the group consisting of A, D, F, G, K, L and S; wherein X2005 is W; wherein X2006 is an amino acid selected from the group consisting of F, H, K and L; wherein X2007 is an amino acid selected from the group consisting of C and HcY; wherein X2008 is an amino acid selected from the group consisting of A. G and S; wherein X2009 is an amino acid selected from the group consisting of a, A, K, L, V, M, m, Nie. p and Sem; wherein X2010 is an aminoacid selected from the group consisting of A , KL, P- R and S; 83 wherein X201 1 is an amino acid selected from the group consisting of D; G and S; wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, 1, M, m, Nle, P, S, Sem and s; wherein X2013 is an amino acid selected from the group consisting of A, D. d. F, G, K, l, S and s; wherein X2014 is an amino acid selected from the group consisting of D, F, G, K, L and S; wherein X2015 is an amino acid selected from the group consisting of A, D, F, G, 1, K, L, M, Nle, S and T; wherein X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nie, S; Sem and Y; wherein X2017 is an amino acid selected from the group consisting of A, D, F, G, K, L, S, T and Y; wherein X2018 is C; wherein X2019 is an amino acid selected from the group consisting of A, F, L, S and V; wherein X2020 is an amino acid selected from the group consisting of F and W; wherein X2021 is an amino acid selected from the group consisting of L and V; wherein X2022 is an amino acid selected from the group consisting of A, D, F, G, K, L, P, R, S and W; and wherein X2023 is either present or absent, whereby in case X2023 is present it an amino acid selected from the group consisting of A. D, F, G, K, L, M, S and Y; and wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018. 84

35. The peptide according to any one of claims 33 to 34, wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, F, G. H, K, L, P and S; wherein X2002 is an amino acid selected from the group consisting of A, F, Hi, K, L, M, R and S; wherein X2003 is an amino acid selected from the group consisting of F, S and Y; wherein X2004 is K; wherein X2005 is W; wherein X2006 is an amino acid selected from the group consisting of F, H, K and L; wherein X2007 is C; wherein X2008 is an amino acid selected from the group consisting of A, G and S, wherein X2009 is an amino acid selected from the group consisting of M, Nle, p, Sem and V; wherein X2W10 is an amino acid selected from the group consisting of A, K, L, P, R and S; wherein X2011 is an amino acid selected from the group consisting of D and S; wherein X2012 is an amino acid selected from the group consisting of D, d. F, f, G, K, k, L, 1, M, Nie, P, Sem and S; wherein X2013 is an amino acid selected from the group consisting of A, D, P G, K, L and S; wherein X2014 is an amino acid selected from the grup consisting of 1 and G; 85 wherein X2015 is an amino acid selected from the group consisting of I and T, wherein X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem and Y; wherein X2017 is an amino acid selected from the group consisting of S and T; wherein X2018 is C; wherein X2019 is an amino acid selected from the group consisting of A, F, L, S and V; wherein X2020 is W; wherein X2021 is an amino acid selected from the group consistng of L and V; wherein X2022 is an amino acid selected from the group consisting of A, F. G, K, L, P, R, S and W; wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, 1), F, G, L M, S and Y; and wherein the peptide comprises a Cyclic structure generated by a linkage between X2007 and X201 8

36. The peptide according to any one of claims 33 to 35, wherein X2001 is an amino acid seected from the group consisting of A. D, F, G, H, K, L and S; wherein X2002 is an amino acid selected from the group consisting of H F, MI and R: wherein X2003 is an amino acid selected from the group consisting of F and Y; wherein X2004 is K; 86 wherein X2005 is W; wherein X2006 is an amino acid selected from the group consisting of F and H; wherein X2007 is C; wherein X2008 is an amino acid selected from the group consisting of A, G and S; wherein X2009 is an amino acid selected from the group consising of M, SCm and V; wherein X2010 is an amino acid selected from the group consisting of K, P and R; wherein X20 11 is D; wherein X2012 is an amino acid selected from the group consisting of F, L, I, M and Scm; wherein X2013 is an amino acid selected from the group consisting of D, G, K and S; wherein X2014 is G; where6iX2015 is anl amio acdselected fr-om- the group conlsistng of an1d T; wherein X2016 is an amino acid selected from the group consisting of D, F, M, Sem and Y; wherein X2017 is an amino acid selected from the group consisting of S and T; wherein X2018 is C; wherein X20 19 is ananino acid selected from the group consisting of A and V; wherein X2020 is W; wherein X2021 is V; wherein X2022 is an ainio acid sected from the group consisting of F, L K, R, P and W 87 wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid sequence selected from the group consisting of A, D, F, M, S and Y; and wherein the peptide comprises as a cyclic stMcture generated by a linkage between X2017 and X2018.

37. The peptide according to any one of claims 33 to 36, wherein the IC 50 of the peptide is less than 1000 AM.

38. The peptide according to any one of claims 34 to 36, wherein the IC% 0 of the pepdde is less than 250 nM.

39. The peptide according to any one of claims 35 to 36, wherein the ICQ of the peptide is less than 50 nM.

40. The peptide according to any one of claims 37 to 39, wherein the ICs 0 is determined by competition ELISA.

41. A peptide that binds TFPL, comprising the following structure of formula (VI): X2001-X2002-F/Y-K-W-F/H-[C-X2008-M/V-X2010-D-X2012-X2013-G-1/T-X2016-S/T C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119) wherein X2001, X2002 and X2023 are each independently present or absent, wherein, if any of X2001, X2002 and X2023 is present, any of X2001, X2002 and X2023, s independently selected from any amino acid; and wherein X2008, X2010 X2012, X2013, X2016 and X2022 are each independently selected from any amino acid

42. The peptde according to clain 41, wherein ICo of the peptide is less than 1000 nM, preferably as determined by competition ELISA.

43. The peptide according to any one of claims 41to 42, wherein 88 X2001 is an amino acid selected from the group consisting of A, D, E, F. G, H, 1, K., L, P, R, S, T, V and W; preferably X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S; and more preferably X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L and S.

44. The peptide according o any one of claims 41 to 43, wherein X2002 is an amino acid selected from the group consisting of A, D, F, F. G. H, 1, K, L, M. P. R. STV, ad W; preferably X2002 is an amino acid selected from the group consisting of A, D, F, G, K, L, M, P, R and S; more preferably X2002 is an amino acid selected from the group consisting of A, F, HK, L, M, R and S; and most preferably X2002 is an amino acid selected from the group consisting of H, F, M and R.

45. The peptide according to any one of claims 41 to 44, wherein X2008 is an amino acid selected from the group consisting of A. 0, R, S and T; and preferably X2008 is an amino acid selected from the group consisting of A, G and S. 46, The peptideaccording to any one of claims 41 to 45, wherein X2010 is an amino acid selected from the group consisting of A, G,1, K, L, P, R, S, T and V; preferably X201 0 is an amino acid selected from the group consisting of A, G, K, L, P, R and S; more preferably X2010 is an amino acid selected from the group consisting of A, K, L, P, R and S; and most preferably X2010 is an amino acid selected from the group consisting of K, P and R.

47. The peptide according to any one of claims 41 to 46, wherein 89 X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, I, K, k, L, 1, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V. v, W and w; preferably X2012 is an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, 1, M, n Nle, P, S, Sem and s; more preferably .X2012 is an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, 1, M, Nle, P. Sem and S; and most preferably X2012 is an amino acid selected from the group consisting of F, L, 1, M and

48. The peptide according to any one of claims 41 to 47, wherein X201 3 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, 1, K, L, R, s, s, T, V and W; preferably X2013 is an amino acid selected from the group consisting of A, D, d, F, G, K, L, S and s; more preferably X2013 is an amino acid selected from the group consisting of A, D, F, G, K, L and S; and most preferably X2013 is an amino acid selected from the group consisting of D, G, K and S.

49. The peptide according to any one of claims 41 to 48, wherein X2016 is an amino acid selected from the group consisting of A, D. E, F, I, K, L. M, Me, R, S, Sem, T, V, W and Y; preferably X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Ser and Y; more preferably X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nie, Sem and B; and most preferably X2016 is an amino acid selected fhrn the group consisting of F, Sem and M.

50. The peptide according to any one of claims 41 to 49, wherein X2022 is an amino acid selected from the group consisting of A, D F, F, G, I, K, L, P, R, S, T, V, and V; preferably X2022 is an amino acid selected from the group consisting of A, D, F, G K, L, P, R, S and W; 90 more preferably X2022 is an amino acid selected from the group consisting of A, F, G, K, L, P, R. S and W; and most preferably X2022 is an amino acid selected from the group consisting of F, L, K, R, P and W.

51. The peptide according to any one of claims 41 to 50, wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, 1, K, L, R, M, S, T, V. W and Y; preferably X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, K, L, M, S and Y; more preferably X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, L M, S and Y; and most preferably X2023 is either present or absent, whereby in case X2023 is present it is amino acid selected from the group consisting of A, D, F, M, S and Y.

52. A peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence of formula VII: Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH2 (VII) (SEQ ID NO: 1040)

53. The peptide according to claim 52, wherein the amino acid sequence identity is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

54. The peptide according to any one of claim 52 to 53, wherein the peptide comprises an amino acid sequence as defined in any of claims 41 to 51.

55. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1210 and 1213-1293.

56. A peptide that binds TFPI, comprising the following structure of formula (VIII): X300I-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011 -X3012 X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120): 91 wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F. G, , K, L, M, N, P, Q, R. S, T, W, E, H and Y; wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L; wherein X3003 is an amino acid selected from the group consisting of A, C. D, E, F. , H, L K, L, M, N, P. Q, R, S,T, W and Y; wherein X3004 is an amino acid selected from the group consisting of A, C, D, E, F, 6, H, 1, K, L, M, N,Q,R, ST, V,W,YandP; wherein X3005 is an amino acid selected from the group consisting of C, D, F, G, H, 1, K, L, M, N, P, R, S, T, V, W and Y; wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H; wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, 1, K, L, N, R, 8, T, W and Y; w herein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, N, N, P Q, R, S, T, V, WA, Y and I; wherein X3009 is an amino acid selected from the group consisting of A, C, F. G H, I, L, M, R, S, T, V, W, Y and K; wherein X3010 is an amino acid selected from the group consisting of A, C, F, ( H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; wherein X3011 is an amino acid selected from the group consisting of A, G, 1, K, L M, N, Q, R, S, T, V. W, Y, C, F and H; 92 wherein X3012 is an amino acid selected from the group consisting of A C, H, KL and R wherein X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and 1; wherein X3014 is an amino acid selected from the group consisting of A, C, F, G, H, 1, L, M, N, Q, R, S, T, V, W, Y and K; wherein X3015 is an amino acid selected from the group consisting of A, K and R; wherein X3016 is an amino acid selected from the group consisting of A, F, K and R; wherein X3i17 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M; wherein X3018 is an amino acid selected from the group consisting of A, C, FL KL, M, Q, R, V, W and Y; wherein X3019 is an amino acid selected from the group consisting of A, C, D, E, F. C, H, K, L, N, P, Q, R, V. W. Y and I; wherein X3020 is an amino acid selected from the group consisting of A, C, F. G, H, K, L, M, N, Q, R, V, W, Y, I and P; and wherein X3021 is an amino acid selected from the group consisting of A C, H. I, K, L, M, N, P, Q R, T, V, W, Y, F and GJ.

57. The peptide according to claim 56, wherein X3001 is either present or absent, whereby in case X3001 is present it is anamino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y; 93 wherein X3002is either present or absent, whereby in case X3002 is present it is an amino selected froni the group consisting of C, F, H, K, R, S, W, Y, G, I and L; wherein X3003 is an amino acid selected from the group consisting of A, C, D, F, G, H, 1, K, L, M, N, P, Q, R, S. T and W; wherein X3004 is an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P; wherein X3005 isan an ano acid selected from the group consisting of C, F, H, 1, K, M, R, T, W and Y; wherein X3006 is an amino acid selected from the group consisting of P, H and A; wherein X3007 is an amino acid selected from the group consisting of C, G, R, W, A and L; wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and 1; wherein X3009 is an amino acid selected from the group consisting of C, I R V and K; wherein X3010 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R, S and T; wherein X301 I is an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H; wherein X3012 is an amino acid selected from the group consisting of H and R; wherein X3013 is an amino acid selected from the group consisting of C, F, K, L, M, R, V and 1; wherein X3014 is an amino acid selected from the group consisting of A, M, C, F, H, 1. L, N, R, S. V, W and K; 94 wherein X30 5 is an amino acid selected from the group consisting of K and R; wherein X3016 is K; wherein X3017 is an amino acid selected from the group consisting of A, C, F, G; 1, K, L, N. Q, R, S;T, V, WH, A and M; wherein X3018 is an amino acid selected from the group consisting of A, K. C, L L, R and wherein X3039 is an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I; wherein X3020 is an amino acid selected from the group consisting of C, H, L, M, R, V, I and P; wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K., L, l, N, Q, R, V, W, Y, F and G.

58. The peptide according to any one of clairm-s 56 and 57, wherein X3001 is an arnino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R S, T, E, H and Y; wherein X3002 is an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L; wherein X3003 is an amino acid selected front the group consisting of A, C, G, H, I, K, L, M R, S, T and W; wherein X3004 is an amino acid selected from the group consisting of A, C, G, H 1, K, L, M, N, R, S, T and P; wherein X3005 is an amino acid selected from the group consisting of C, F, H, K. R and W. 95 wherein X3006 is an amino acid selected from the group consisting of A, P and H; wherein X3007 is an amino acid selected from the group consisting of L, C, R and W; wherein X3008 is an amino acid selected from the group consisting of A, C, F, H, K, R, V, W. Y and I; wherein X3009 is an amino acid selected from the group consisting of C, R, V and K; wherein X3010 is an amino acid selected from the group consisting of A, C, K, L, Q, R and S; wherein X3011 is an amino acid selected from the group consisting of 1, K, L, M, R, V, W, C, F and H; wherein X30 12is H; wherein X301 3 is an amino acid selected from the group consisting of C, KR V and I; wherein X3014 is an amino acid selected from the group consisting of A, 5, C, F, H, 1. R and K; wherein X301 5 is an amino acid selected from the group consisting of K and R; wherein X3016 is R; wheirein X301 7 is an amino acid selected from the group consisting of C, G, 1, K, L, N, Q7 R, S. T, V, H, A and M; wherein X3018 is an ammo acid selected from the grup consisting of K. C, I, R and W; wherein X3019 is an amino acid selected from the group consisting of C, E, H, K, R and I; wherein X3020 is an amino acid selected from the group consisting of C, M, I and P; 96 wherein X3021 is an amino acid selected from the group consisting of A, C, H, , K, L, M, N, Q, R, V, W, F and G.

59. The peptide according to any one of claims 56 to 58, wherein the IC 5 o of the peptide is less than 50,000 nM,

60. The peptide according to any one of claims 57 to 58, wherein the IC 50 of the peptide is less than 10.000 nM.

61. The peptide according to claim 58, wherein the IC 50 of the peptide is less than 5,000 nM.

62. The peptide according to any one of claims 59 to 60, wherein the IC 50 is determined by competition ELISA.

63. A peptide that binds TFPI, comprising the following structure of formula (IX): X3001 -- X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X301 0-X30 11-H X3013-X3014-K/R-R-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121) wherein X3001 and X3002 are independently either present or absent, wherein, if X3001 and/or X3002 are present, X3001 and/or X3002 are independently selected from any amino acid, and wherein X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X301 1, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid.

64. The peptide according to claim 63, wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C , D, F, G, , K. L, N, P, Q, R, S. T, W, E, H and Y; 97 preferably X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, G, L. K. L, M. N, P, Q, R, S. T, W, E, H and Y; and more preferably X3001 is an amino acid selected front the group consisting of A, C, D, G, K, L, M, N, P, R, S; T, E, -and Y,

65. The peptide according to any one of claims 63 to 64, wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P,. R, S, T, W, Y, G, I and L: preferably X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L; and more preferably X3002 is an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L.

66. The peptide according to any one of claims 63 to 65, wherein X3003 is an amino acid selected from the group consisting of A, C, D, E, F C, H, I, K, L, M, N, P, Q, R, S, T, W, and Y; preferably X3003 is an amino acid selected from the group consisting of A, C. D, F, G, H, , K, L, M, N, P, Q, R, S, T and W; and more preferably X3003 is ar amino acid selected from the group consisting of A, C, G, H, 1, K, L, M, R, S, T and W. 67, The peptide according to any one of claims 63 to 66, wherein X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V. W, Y and P; 98 preferably X3004 is an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M N, R, S, T, V and P; and more preferably X3004 is an amino acid selected from the group consisting of A, C, G, H. 1, K, L, M, N, R, S, T and .P.

68. The peptide according to any one of claims 63 to 67, wherein X3005 is an amino acid selected from the group consisting of C, D, F. G, GIH L K L, M, N, P. R, S, T, V, W and Y; preferably X3005 is an amino acid selected from the group consisting of C F, H7 K, I R T, W and Y; and more preferably X3005 is an amino acid selected from the group consisting of C F, H, K, R and WV.

69. The peptide according to any one of claims 63 to 68, wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H and preferably X3006 is an amino acid selected from the group consisting of P, H and A.

70. The peptide acc ording to any one of claims 63 to 69, wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F G. H, I, K, L, N, R, S, T, W and Y; preferably X3007 is an amino acid selected from the group consisting of C, G, R, W, A and L; and more preferably X3007 is an amino acid selected from the group consisting of L, C, R and W.

71. The peptide according to any one of claims 63 to 70, wherein 99 X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P. Q, R, S, T, V, W, Y and I; preferably X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and 1; and more preferably X3008 is an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and 1.

72. The peptide according to any one of claims 63 to 71, wherein X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K; preferably X3009 is an amino acid selected from the group consisting of C, I, R, V and K; and more preferably X3009 is an amino acid selected from the group consisting of C, R, V and K.

73. The peptide according to any one of claims 63 to 72, wherein X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; preferably X3010 is an amino acid selected from the group consisting of A, C, G, H, , K, L, M, Q, R, S and T; and more preferably X301 0 is an amino acid selected from the group COnsisting of A, C, K, L, Q, R and S.

74. The peptide according to any one of claims 63 to 73, wherein X301 i is an amino acid selected from the group consisting of A, G, 1, K, L M N, Q, R, S, T, V, V, Y, C., F and H; 100 preferably X301 1 is an amino acid selected from the group consisting of A, , , L M, R, S, V, W, C, F and H; and more preferably X301 I is an amino acid selected from the group consisting of , K, L, M, R, V, W, C, F and H.

75. The peptide according to any one of claims 63 to 74, wherein X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I; preferably X301 3 is an amino acid selected from the group consisting of C. F, K, L, M, R, V, and I; and more preferably X301 3 is an amino acid selected from the group consisting of C, K, R, V and

76. The peptide according to any one of claims 63 to 75, wherein X3014 is an amino acid selected from the group consisting of A, C, F, G, H, , L, M N, Q, R, S, T, V, W, Y and K; preferably X3014 is an amino acid selected from the group consisting of A, M, C, F, H, 1, L, N, R, S, V, W and K; and more preferably X3014 is an amino acid selected from the group consisting of A, S, C, F, H, , R and K. 77 The peptide according to any one of claims 63 to06, wherein X30 7 is an amino acid selected from the group consisting of A, C, F, G, I K, L, N, Q, R S T, V, W, Y, H, A and M; preferably X3017 is an amino acid selected from the group consisting of A, C, F, G, 1, K, L, N, Q, R, S, '. V, W, H,A and M; and 101 more preferably X3017 is an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M,

78. The peptide according to any one of claims 63 to 77, wherein X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y; preferably X3018 is an amino acid selected from the group consisting of A, K, C, I, L, R and W; and more preferably X3018 is an amino acid selected from the group consisting of K, C, , R and W.

79. The peptide according to any one of claims 63 to 78, wherein X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R. V, W. Y and i; preferably X3019 is an amino acid selected from the group consisting of A, C, E, H, K, N, Q, R and I; and more preferably X3019 is an amino acid selected from the group consisting of C, E, TI, K, R and 1.

80. The peptide according to any one of claims 63 to 79, wherein X3020 is an amino acid selected from the group consisting of A. C. F, G. H, K, L, M, N, Q, R, V, W, Y, I and P; preferably X3020 is an amino acid selected from the group consisting of C, H, L, M, R, V, I and P; and more preferably X3020 is an amino acid selected from the group consisting of C, M, I and P, 102

81. The peptide according to any one of claims 63 to 80, wherein X3021 is an amino acid selected front the group consisting of A, C, H, 1 K, L, M, N, P, Q, R, T, V, W, Y, F and G; preferably X3021 is an amino acid selected from the group consisting of A, C, H, 1, K, L, M, N, Q, R, V, W, Y, F and G; and more preferably X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G.

82. The peptide according to any one of claims 63 to 81, wherein the IC 50 of the peptide is less than 50,000 nM, preferably less than 10,000 nM and more preferably less than 5,000 nM,

83. A peptide that binds TFPI, comprising an amino acid sequence of at least 60 % identity to the sequence of formula (X): Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (X) (SEQ ID NO: 223)

84. The peptide according to claim 83, wherein the amino acid sequence identity is at least 60%, 65%; 70%, 75%, 80%, 85%, 90%, 95% or 100%.

85. The peptide according to any one of claim 83 to 84., wherein the peptide comprises an amino acid sequence as defined in any of claims 56 to 82.

86. A peptide conssting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2126, 2128-296, and 2298-2498.

87. A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3048, 3051-3053, 3055, 3057-3064, and 3066-3108.

88. The peptide according to any one of claims I to 87, wherein the peptide binds to TFPL 103

89. The peptide according to any one of claims 1 to 88, wherein said peptide inhibits TFPI activity, whereby preferably the peptide binds to TFPT I-alpha with a dissociation constant of less than 10 pM.

90. The peptide according to any one of claims 1-89, wherein the peptide is conjugated to a polyethylene glycol (PEG) moiety. 91 A peptide according to any one of claims 1 to 90 for use in a method for the treatment of a subject.

92. The peptide according to claim 91, wherein the method is for the treatment of a blood coagulation disorder.

93. Use of a peptide according to any one of claims 1 to 90 for the manufacture of a medicament. 94, Use of a peptide according to any one of claims I to 90 for the manufacture of a medicament for the treatment of a blood coagulation disorder,

95. A method for treating a blood coagulation disorder in a subject, the method comprising administering to the subject a peptide that inhibits TFPI activity, wherein the peptide is administered in a amount sufficient to treat the blood coagulation disorder in the subject.

96. The method according to claim 95, wherein the peptide is different from a naturally occurring peptide which inhibits TFPI activity.

97. The method according to any one of claims 95 to 96, wherein the peptide is a peptide as defined in any one of claims I to 90. 98, 'The method according to any one of claims 95 to 96, wherein the peptide comprises 40 amino acids or less, preferably the peptide comprises 25 amino acids or less, and more preferably the peptide comprises 10 amino acids or less. 104 99, The method according to any one of claims 95 to 98, preferably claim 98, wherein the peptide comprises one or more b-amino acids.

100. The method according to any one of claims 95 to 99, preferably 98 to 99, wherein the peptide comprises one or more non-natural amino acids.

101. The method according to claim 100, wherein the one or more non-natural amino acids are selected from the group consisting of 2-aminobutyric acid, 2-amino-isobutyric acid, f alanine, f-homoglutamatic acid, pA-homophenylalanine, Q-homolysine, f-homoleucine, f3 homoasparagine, p3homoglutamine, p-homoarginine, p-homoserine, p-homotyrosine, p homoaspartic acid, 3-homovaline, $-homoasparagin, (S)-cyclohexylaanine, (S)-citrulin, (S) 2,4-diaminobutyric acid, (S)-2,4-diaminobutyric acid, (S)-diaminopropionic acid, (S)-2 propargylglycine, (S)N(omega)-nitro-arginine, L-homophenyllanine, S)-homo-arginine, (S)-homo-citrulline, (S)-homo-cysteine, (S)-2-amino-5-rnethyl-hexanoic acid, (S)-homo lysine, (S)-norleucine, (S)-N-methylalanine, (S)-N-methyl-aspartic acid, (S)-N-methyl glutarnic acid, (S)-N-methyl-phenylalanine, N-methyl-glycine, (S)-N-methyl-lysine, (S)-N methyl-leucine, (S)-N-methyl-arginine, (S)-N-methyl-serine, (S)-N-methyl-valine, (S)-N methyl-tyrosine, (S)-2-amino- pentanoic acid, (S)-2-pyridyl-alanine, (S)-ornithine, L phenylglycin, 4-phenyl-butyric acid and selenomethionine.

102. Thc method according to any one of claims 95 to 101, wherein the subject is Factor VIII or Factor IX deficient

103. The method according to any one of claims 95 to 102, wherein the peptide binds to TFPI I alpha with a dissociation constant of less than 10 pm.

104. The method according to any one of claims 95 to 103 wherein the peptide is linked to an effector moiety.

105. The method according to any one of claims 95 to 103, wherein the peptide is linked to biotin.

106. A pharmaceutical compositing comprising a peptide as defined any one of claims 90 and a pharmaceutical acceptable carrier. 105

107. The pharmaceutical composition according to claim 106, wherein the composition comprises a further pharmaceutically effective agent.

108. The pharmaceutical composition according to any one of claims 106 to 107, wherein the pharmaceutical composition is for use in a method as defined in any one of claims 94 to 106.

109. A method for targeting a cell displaying TFPJ, wherein the method comprises contacting the cell with a peptide as defined in any one of claims 1 to 90.

110. The method of claim 109, wherein the cell is in a mammal, and contacting the cel comprises administering the peptide to the mammal. 11L The method according to any one of claims 109 to 110, wherein the further comprises detecting peptide binding to TFPI displayed on the cell.

112. The method according to any of claims 109 to I ll, wherein the peptide is conjugated to a moiety, wherein such moiety is preferably selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

113. The method according to claim 111, wherein peptide-TFPI binding is detected by detecting an interaction partner complexed with the peptide or the moiety.

114. The method daccoding to claim r13,wherein the interaction partner isselected from the group consisting of an antibody, an anticalin, an aptamer, and a spiegelmer. 11 The method according to any one of claims 113 to 114, wherein the intention partner comprises a detection moiety,

116. The method according to claim I 15, wherein the detection moiety is selected from the group consisting of a dye, a fluorescence dyen radionuclide, a rdionnelide-containing complex, and an enzyme. 106

117. A method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the method comprises administering to the subject a peptide as defined in any one of daims 1-90, wherein the peptide is conjugated to a therapeutic agent.

118. A method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the method comprises administering to the subject a peptide as defined in any one of claims 1-90, and administering to the subject an interaction partner that (a) binds the peptide and (b) is a therapeutically agent or is conjugated to a therapeutic agent.

119. The method according to claim 118. wherein the interaction partner is selected from the group consisting of an antibody, an anticalin, an aptamer and a spiegelmer.

120. The method according to any one of claims 117 to 119, wherein the therapeutically effective agent is selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionuclide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

121. The method according to any one of claims 117 to 120, wherein the disease can be treated or the disease symptoms can be ameliorated by the inhibition of TFPL

122. The method according to claim. 121, wherein the disease is a blood coagulation disorder,

123. A method for diagnosing a subject suffering from a disease or being at risk of suffering from a disease, comprising (a) administering to the subject a peptide as defined in any one of claims 1-90 conjugated to a detectable moiety and (b) detecting the detectable moiety.

124. A method for diagnosing a subject suffering from a disease or being at risk of suffering from a disease, comprising (a) administering to the subject a peptide as defined in any one of claims 1-90 (b) administering to the subject an interaction partner conjugated to a detectable moiety, and (c) detecting the detectable moiety. 107

125. The method according to claim 124, wherein the interaction partner is selected from the group consisting of an antibody, an anticalin, an aptamer, and a spiegelmer.

126. The method according to any one of claims 123 to 125, wherein the detectable moiety is selected from the group consisting of a dye, a fluorescence dye, a radionuclide, a radionudide-containing complex, an enzyme, a toxin, an antibody, and a cytotoxic agent.

127. The method according to any one of claims 123 to 126, wherein the disease is a disease which is associated with TFPI, which can be treated or the symptoms of which can be ameliorated by the inhibition of TFPI.

128. The method according to claim 127, wherein the disease is a blood coagulation disorder.

129. A method for purifying TFPI, wherein the method comprises a) contacting a sample containing TFPI with a peptide as defined in any one of claims 1-90 under conditions appropriate to form a complex between TFPI and the peptide; b) removing the complex from the sample; and, optionally, c) dissociating the complex to release TEPh

130. The method according to claim 131, wherein the peptide is immobilized to a support, preferably a solid support.

131. The method according to any one of claims 129 to 130, wherein the peptide is immobilized to a chromatography stationary phase, and step (c) comprises eluting TFPI bound to the immobilized peptide. 133 The method according to claim 32 wherein the peptide is purified via affinity chromatography. 108